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CLAIMING A CELL RESET BUTTON: 
INDUCED PLURIPOTENT STEM CELLS 
AND PREPARATION METHODS AS 
PATENTABLE SUBJECT MATTER 
Abstract: In 2006, a team of scientists discovered a method to create pluripo-
tent stem cells—cells that have the potential to become almost any other type of 
cell in the human body—by inserting specific genes into a skin cell. The result-
ing cells were called induced pluripotent stem cells (“iPS cells”). The ability to 
manufacture stem cells could eventually eliminate the need to harvest stem cells 
from embryos, thereby rendering the embryonic stem cell debate irrelevant. 
Should a patent claim directed toward an iPS cell-related technology be chal-
lenged in the future, the absence of a bright-line test for patentable subject mat-
ter could present challenges to the presiding court. This Note proposes two new 
standards by which courts should evaluate whether products of nature and pro-
cesses in the life sciences are patentable subject matter and, applying those 
standards, concludes that sufficiently narrow claims directed to iPS cells and 
preparation methods would likely be upheld as patentable subject matter. 
INTRODUCTION 
The medical use of pluripotent stem cells was, for a time, one of the 
most contested bioethical issues in the United States.1 Pluripotent stem cells 
are naturally occurring cells that have the potential to differentiate into al-
most any type of cell in the body.2 Because of their unique differentiation 
capabilities, pluripotent stem cells have many different applications in med-
icine, including the treatment of various diseases through cell regeneration.3 
                                                                                                                           
 1 See President George W. Bush, Remarks on Stem Cell Research (Aug. 9, 2001), in THE 
PRESIDENT’S COUNCIL ON BIOETHICS, MONITORING STEM CELL RESEARCH app. B (2004), avail-
able at https://bioethicsarchive.georgetown.edu/pcbe/reports/stemcell/appendix_b.html [https://
perma.cc/7UVZ-T8TH] (explaining former President George W. Bush’s views against embryonic 
stem cell research); Mara Godoy et al., Key Moments in the Stem Cell Debate, NPR (Nov. 20, 2007), 
http://www.npr.org/templates/story/story.php?storyId=5252449 [http://perma.cc/6QG5-X8QN] (out-
lining the scientific and political history of stem cell research); Paul Krzyzanowski, Stem Cells: 
The Quiescent Issue in U.S. Elections, SIGNALS (Sept. 20, 2012), http://www.signalsblog.ca/stem-
cells-the-quiescent-issue-in-us-elections/ [http://perma.cc/87J3-AR8S] (describing the stem cell 
debate as one of the dominant issues in pre-2012 U.S. presidential elections but “conspicuously 
absent” in the 2012 electoral debates). 
 2 See Ian Murnaghan, Multipotent Stem Cells, EXPLORE STEM CELLS, http://www.explore
stemcells.co.uk/MultipotentStemCells.html [http://perma.cc/JVQ7-SRZ5] (explaining the origin 
of pluripotent stem cells in the human embryo). 
 3 See id. 
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Under the right conditions, pluripotent stem cells can develop into special-
ized cells that can ultimately replace diseased cells and tissues.4 
Prior to 2006, the only pluripotent stem cells in existence that could 
differentiate into nearly every type of bodily cell and that could be success-
fully maintained in a laboratory were embryonic stem cells (“ESCs”).5 Such 
stem cells, however, could not be harvested without destroying a human 
embryo. 6  Opponents of stem cell research argue that unborn embryos 
should be protected and should not be sacrificed for medical purposes.7 Al-
ternatively, proponents of stem cell research argue that the stem cell therapy 
should be explored and developed because stem cells have the potential to 
significantly improve the quality of life of many people with debilitating 
diseases.8 Because the harvesting and use of embryonic stem cells for med-
ical research raises ethical questions, embryonic stem cell research has been 
the subject of intense political debate for nearly two decades.9 
Since 2006, however, the debate surrounding embryonic stem cell re-
search has been on a steady decline.10 This decline has not been fueled by 
                                                                                                                           
 4 See id.; What Are the Potential Uses of Human Stem Cells and the Obstacles That Must Be 
Overcome Before These Potential Uses Will Be Realized?, NAT’L INSTS. OF HEALTH (Mar. 5, 
2015), http://stemcells.nih.gov/info/basics/pages/basics6.aspx [http://perma.cc/TJ4F-KMQ3] 
[hereinafter Potential Uses] (outlining the conditions that can potentially be treated using pluripo-
tent stem cells). 
 5 See Murnaghan, supra note 2. Although stem cells can also be harvested from the blood or 
organs of adults, ESCs have several advantages that make them better suited to scientific research. 
See id. ESCs can differentiate into almost any type of cell in the body, whereas adult stem cells 
can only differentiate into a limited number of cell types. See id. Moreover, ESCs are easily grown 
in a laboratory and are capable of almost unlimited division when placed in cell culture, whereas 
adult stem cells are not grown easily after isolation and do not multiply as readily. See id. Because 
stem cell research requires the generation of large numbers of cells, having cell lines that can grow 
and divide readily is critical for successful experimentation. See id. For this reason, ESCs are 
generally a better research tool than adult stem cells. See id. 
 6 See Murnaghan, supra note 2 (explaining how embryonic stem cells are obtained); An Over-
view of Stem Cell Research, CTR. FOR BIOETHICS & HUMAN DIGNITY, TRINITY INT’L UNIV. (Aug, 
2009), https://cbhd.org/stem-cell-research/overview [https://perma.cc/LH2C-GBG3] (last updated 
Aug. 2009) (explaining how embryonic stem cells are obtained and the principal differences be-
tween embryonic and adult stem cells). 
 7 See An Overview of Stem Cell Research, supra note 6 (providing an overview of the ethical 
debate surrounding the use of embryonic stem cells for research purposes). 
 8 See id. 
 9 See John A. Robertson, Embryo Stem Cell Research: Ten Years of Controversy, 38 J.L., 
MED. & ETHICS 191, 191 (2010); An Overview of Stem Cell Research, supra note 6 (providing an 
overview of the ethical debate surrounding the use of embryonic stem cells for research purposes). 
 10 See Krzyzanowski, supra note 1 (describing the stem cell debate as one of the dominant 
issues in pre-2012 U.S. presidential elections but “conspicuously absent” in the 2012 electoral 
debates). But see John Farrell, The Line Between Embryonic and Pluripotent Stem Cell Research 
Is Blurring, FORBES (Sept. 28, 2012 12:35PM), http://www.forbes.com/sites/johnfarrell/2012/09/
28/the-line-between-embryonic-and-pluripotent-stem-cell-research-is-blurring/ [http://perma.cc/P2DR
-YCYE] (arguing that iPS cells could also have the ability to create life, which would render the 
embryonic stem cell debate still relevant). 
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shifting ethical beliefs but has instead resulted from one of the most signifi-
cant discoveries of the past century in the biological field.11 In 2006, Dr. 
Shinya Yamanaka of the University of Kyoto was credited with discovering 
induced pluripotent stem cells (“iPS cells”).12 Dr. Yamanaka inserted four 
genes into a skin cell, which essentially “reprogrammed” the skin cell to 
become a cell resembling a pluripotent stem cell.13 Because of Dr. Yama-
naka’s discovery, there is a wide new range of scientific research on plu-
ripotent stem cells that can now be carried out.14 Moreover, such research 
can be performed without confronting the major bioethical dilemma of de-
stroying human embryos. 15 Since Dr. Yamanaka’s discovery, the United 
States Patent and Trademark Office (“USPTO”) has granted patents on iPS 
                                                                                                                           
 11 See Kazutoshi Takahashi et al., Induction of Pluripotent Stem Cells from Adult Human Fibro-
blasts by Defined Factors, 131 CELL 861, 861 (2007) [hereinafter Takahashi et al. 2007] (explaining 
how, using factors Oct3/4, Sox2, Klf4, and c-Myc, adult human fibroblasts were reprogrammed to 
become iPS cells, which resembled naturally occurring stem cells in morphology, gene expression, 
and proliferation, among other characteristics); Kazutoshi Takahashi et al., Induction of Pluripotent 
Stem Cells from Mouse Fibroblasts and Adult Fibroblast Cultures by Defined Factors, 126 CELL 
663, 663 (2006) [hereinafter Takahashi et al. 2006] (explaining that differentiated cells, such as fi-
broblasts, can be reprogrammed into an embryonic-like state); Paul Knoepfler, Induced Pluripotent 
Stem Cells Are Similar to Cancer Cells, but Nobel Prize Still Well-Deserved, HUFFINGTON POST 
(Oct. 12, 2012), http://www.huffingtonpost.com/paul-knoepfler/induced-pluripotent-stem-cells-cancer
-cells_b_1926016.html [http://perma.cc/S5PW-H5RT] (discussing the impact of Dr. Yamanaka’s 
work on the field of stem cell research); Dan Vergano, Al Gore on Board for $20M Stem Cell 
Venture, USA TODAY (Apr. 14, 2009), http://usatoday30.usatoday.com/tech/science/ethics/2009-04-
14-gore-stem-cells_N.htm [http://perma.cc/XP8H-FGCH] (discussing the attraction of researchers 
and investors to emerging iPS cell technologies). 
 12 See Takahashi et al. 2006, supra note 11, at 663; Gina Kolata, Scientists Bypass Need for 
Embryo to Get Stem Cells, N.Y. TIMES (Nov. 21, 2007), http://www.nytimes.com/2007/11/21/
science/21stem.html?_r=1& [http://perma.cc/4MGH-DBHV] (describing iPS cells and how they 
were expected to impact the medical field); Alice Park, A Breakthrough on Stem Cells, TIME (Dec. 
11, 2007), http://content.time.com/time/health/article/0,8599,1685965,00.html [http://perma.cc/7XBX-
VUCK] (reporting the discovery of iPS cells). 
 13 See Takahashi et al. 2007, supra note 11, at 862 (observing that, two weeks following in-
troduction of Oct3/4, Sox2, Klf4, and c-Myc into fibroblast cells, some clusters of cells appeared 
that did not resemble the original fibroblast cells, suggesting that the cells had been reprogrammed 
to a stem cell-like state); see also Takahashi et al. 2006, supra note 11, at 666 (observing that the 
same four factors used in mouse fibroblasts produced similar colonies, or clusters of cells, that did 
not resemble the original fibroblasts). 
14 See Takahashi et al. 2007, supra note 11, at 862 (explaining that the reprogrammed fibro-
blasts resembled naturally occurring stem cells “in morphology, proliferation, surface antigens, 
gene expression, epigenetic status of pluripotent cell-specific genes, and telomerase activity”); 
Kolata, supra note 12 (explaining that iPS cells are advantageous to researchers because they will 
genetically match the donor); Lori J. Schroth, Researchers Create Embryonic Stem Cell Without 
Embryo, HARV. GAZETTE (Jan. 29, 2014), http://news.harvard.edu/gazette/story/2014/01/research
ers-create-embryonic-stem-cells-without-embryo/ [http://perma.cc/8QYV-Z3D2] (discussing the 
possibility that researchers may one day be able to create stem cells from a person’s blood sample, 
which could allow scientists to create tissue specific to that individual). 
 15 See Takahashi et al. 2007, supra note 11, at 862; Kolata, supra note 12; Schroth, supra note 
14. 
1580 Boston College Law Review [Vol. 56:1577 
cell lines, iPS cell preparation methods, and nuclear reprogramming fac-
tors.16  
The U.S. Supreme Court has decided several patent cases in the past 
few decades relating to the patentability of life sciences inventions and 
methods.17 The Court has not, however, articulated a clear-cut standard as to 
what, in the context of life sciences products and methods, meets the pa-
tentable subject matter requirement. 18  Courts have routinely found that 
products of nature are not patentable subject matter under 35 U.S.C. 
§ 101.19 Despite this, in 1980 in Diamond v. Chakrabarty, the U.S. Supreme 
Court held that a bacterium with an inserted foreign gene is patentable sub-
ject matter.20 An iPS cell is similar to the bacterium in Chakrabarty in the 
sense that both contain foreign genes.21 Unlike the bacterium, however, an 
iPS cell is meant to resemble an unpatentable natural product.22 Should a 
patent claim directed toward an iPS cell-related technology be challenged in 
the future on patentable subject matter grounds, such a challenge would 
present a unique dilemma to the presiding court.23 
This Note proposes new standards that courts should employ when 
considering challenges to iPS cell line patents and iPS cell preparation 
method patents based on the § 101 patentable subject matter requirement.24 
Part I provides an overview of the patentable subject matter requirement 
                                                                                                                           
 16 See infra note 74 and accompanying text (explaining patents granted on iPS cell technolo-
gies). 
 17 See infra notes 95–122 and accompanying text (explaining case law addressing patentable 
subject matter in the context of the life sciences). 
 18 See infra notes 95–122 and accompanying text (explaining current status of standard for 
determining patentable subject matter in the context of the life science). 
 19 See 35 U.S.C. § 101 (2012) (identifying as patentable subject matter any “useful process, 
machine, manufacture, or composition of matter, or any new and useful improvement thereof”); 
Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (stating that “laws of nature, physical phe-
nomena, and abstract ideas” are not patentable subject matter); Parker v. Flook, 437 U.S. 584, 598 
(1978); Gottschalk v. Benson, 409 U.S. 63, 67 (1972); Funk Bros. Seed Co. v. Kalo Inoculant Co., 
333 U.S. 127, 130 (1948). 
 20 See Chakrabarty, 477 U.S. at 310 (stating that the patentee’s bacterium possessed “marked-
ly different characteristics from any found in nature and one having the potential for significant 
utility” and that the bacterium was “not nature’s handiwork”). 
 21 See id. (explaining that the foreign genes the patentee inserted into the bacterium at issue 
enabled the bacterium to degrade hydrocarbons); Takahashi et al. 2007, supra note 11, at 862 
(outlining the process by which the four reprogramming factors were introduced into fibroblast 
cells). 
 22 See Takahashi et al. 2007, supra note 11, at 861 (explaining that Oct3/4, Sox2, Klf4, and c-
Myc were chosen over other reprogramming factors because fibroblasts reprogrammed with these 
four factors showed, over time, a high degree of similarity to naturally occurring stem cells). 
 23 See Chakrabarty, 477 U.S. at 310 (finding a bacterium that contained foreign genes and 
that did not resemble any other bacterium found in nature was patentable subject matter); 
Takahashi et al. 2007, supra note 11, at 861–62 (explaining the discovery of iPS cells and how 
these cells contain foreign genes but do resemble other cells found in nature). 
 24 See infra notes 149–207 and accompanying text. 
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and the invention of iPS cells.25 Part II discusses the patentable subject mat-
ter requirement in the context of the life sciences.26 Part III discusses the 
problem of patent thickets in the life sciences and how courts have handled 
the issue.27 Part IV proposes two standards that can be used to evaluate 
whether patents on inventions that are derivatives of natural products and 
patents on biological methods are patentable subject matter.28 Part V applies 
the two proposed standards to iPS cell technologies.29 Finally, Part VI ad-
dresses the implications that a ruling upholding or invalidating claims to 
iPS cell technologies would have on the fields of biological research, medi-
cine, and patent law.30 
I. INDUCED PLURIPOTENT STEM CELL TECHNOLOGY AND THE PATENTABLE 
SUBJECT MATTER REQUIREMENT: A BACKGROUND 
Section A provides an overview of the patentable subject matter re-
quirement. 31  Section B discusses how the patentable subject matter re-
quirement is applied to methods and processes.32 Section C discusses the 
development of induced pluripotent stem cells (“iPS cells”) and why the 
patentability of iPS cell lines and preparation methods remains unclear.33 
A. An Overview of the Patentable Subject Matter Requirement 
Title 35 of the U.S. Code establishes the requirements for patentabil-
ity.34 In order for a technology to be patentable, the technology must be (1) 
useful, (2) novel, (3) nonobvious, and (4) patentable subject matter.35 
                                                                                                                           
 25 See infra notes 34–79 and accompanying text. 
 26 See infra notes 80–122 and accompanying text. 
 27 See infra notes 123–148 and accompanying text. 
 28 See infra notes 149–207 and accompanying text. 
 29 See infra notes 208–233 and accompanying text 
 30 See infra notes 234–242 and accompanying text. 
 31 See infra notes 34–47 and accompanying text. 
 32 See infra notes 48–53 and accompanying text 
 33 See infra notes 54–79 and accompanying text. 
 34 See 35 U.S.C. § 101 (setting forth patentability requirements). 
 35 Id. The utility requirement for obtaining a patent is stated in 35 U.S.C. § 101. See id. An 
invention is “useful” if it provides some identifiable benefit and is capable of use. See Brenner v. 
Manson, 383 U.S. 519, 528–29 (1966) (holding that a novel process for synthesizing a steroid was 
not useful because the steroid served no known function); Utility Examination Guidelines, 66 Fed. 
Reg. 1092, 1092 (Jan. 5, 2001) (providing that a patent application must express a specific, credi-
ble, and substantial utility in order for the inventor to be awarded a patent). Because iPS cells 
show significant promise as a research tool and possible source of medical treatments, plaintiffs 
would not be likely to challenge iPS cell patents on utility grounds. See Takahashi et al. 2007, 
supra note 11, at 861; Monya Baker, Adult Cells Reprogrammed to Pluripotency, Without Tu-
mors, NATURE REPORTS: STEM CELLS (Dec. 6, 2007), http://www.nature.com/stemcells/2007/
0712/071206/full/stemcells.2007.124.html [http://perma.cc/P5MJ-AMTZ]. The novelty require-
ment provides that an invention is not patentable if it was known to the public prior to the patent’s 
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The patentable subject matter requirement dictates that only inventions 
that fall into one of four categories—processes, machines, manufactures, 
and compositions of matter—are eligible to be patented.36 The purpose of 
the patentable subject matter requirement is to prevent a patent monopoly 
on certain tools that are necessary for inventors to create new and useful 
inventions.37 The limits of these four categories are not perfectly clear, as 
Congress has left the courts with the task of defining what should be in-
cluded under this statute.38 
Courts have historically construed the boundaries of patentable subject 
matter rather broadly.39 Courts have created three categories of judicial ex-
clusions to patentable subject matter: laws of nature, physical phenomena, 
and abstract ideas.40 A claim directed toward an invention that falls within 
one of these three judicial exclusions is not patentable under § 101.41 In cre-
ating these judicial exclusions, courts sought to keep this subject matter in 
                                                                                                                           
priority date. 35 U.S.C. §§ 101–102 (2012). A patent, a patent application, or an invention that 
was known of or in use in the United States prior to the applicant priority date will render an in-
vention non-novel. 35 U.S.C. §§ 101–102; Kimberly-Clark Corp. v. Johnson & Johnson, 745 F.2d 
1437, 1453 (Fed. Cir. 1984) (citing Graham v. John Deere Co., 383 U.S. 1, 6 (1966)) (explaining 
that proof of conception alone does not qualify as prior art). Additionally, an invention must be 
nonobvious, or “sufficiently inventive,” in order to be patented. 35 U.S.C. § 103. 
 36 35 U.S.C. § 101; Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347, 2350 (2014) (ex-
plaining that the “buildin[g] block[s] of human ingenuity” are not patentable, whereas inventions 
“that integrate the building blocks into something more” may be patentable) (citing Mayo Collab-
orative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1303 (2012) (finding invalid a patent 
claiming the correlation between concentrations of metabolites in the blood and the effectiveness 
of a drug)). 
 37 Alice, 134 S. Ct. at 2350; see Brenner, 383 U.S. at 535 (explaining that the USPTO may 
not grant patent applications that are so broad they “engross” a field); Dmitry Karshtedt, The 
Completeness Requirement in Patent Law, 56 B.C. L. REV. 949, 953 (2015) (describing how the 
doctrines of utility, written description, and patentable subject matter are used to deem potentially 
problematic classes of inventions unpatentable). 
 38 Anu R. Sawkar, Are Storylines Patentable? Testing the Boundaries of Patentable Subject 
Matter, 76 FORDHAM L. REV. 3001, 3009–12 (2008) (discussing the statutory framework of the 
patentable subject matter requirement); Brandon Smith, The Patentability of Human Embryonic 
Stem Cells in Light of Myriad, 96 J. PAT. & TRADEMARK OFF. SOC’Y 112, 117 (2014) (discussing 
how the lack of clarity surrounding the patentable subject matter requirement has left uncertain 
whether certain life sciences inventions are patentable). 
 39 35 U.S.C § 101; see Chakrabarty, 447 U.S. at 309 (“Congress intended statutory subject 
matter to ‘include anything under the sun that is made by man.’” (quoting S. REP. NO. 82-1979, at 
5 (1952))). 
 40 See Chakrabarty, 447 U.S. at 309 (articulating three judicial exclusions to patentable sub-
ject matter); Parker v. Flook, 437 U.S. 584, 598 (1978) (offering a method of calculating alarm 
limit values to be not patentable subject matter); Gottschalk v. Benson, 409 U.S. 63, 67 (1972) 
(establishing a mathematical formula used in connection with a computer to be an unpatentable 
process); Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (determining 
claims directed to inoculants containing several species of nitrogen-fixing bacteria to be invalid). 
 41 See Chakrabarty, 447 U.S. at 309 (stating that laws of nature, natural phenomena, and 
abstract ideas cannot be patented); Parker, 437 U.S. at 598; Gottschalk, 409 U.S. at 67; Funk 
Bros. Seed Co., 333 U.S. at 130. 
2015] Induced Pluripotent Stem Cells and New Patentability Standards 1583 
the public domain and free from monopoly.42 Courts have not, however, 
articulated a bright-line standard beyond these three judicial exclusions.43 
The patentable subject matter requirement has been enmeshed in un-
certainty in recent years.44 In the field of biotechnology, inventions are of-
ten composed of or resemble products of nature.45 In these cases, it is often 
unclear whether the invention falls within a judicial exception.46 Because 
courts have not clearly defined the judicial exceptions to patentable subject 
matter, it is often difficult to determine whether a product or method patent 
in the biotechnology sphere is in fact patent-eligible subject matter.47 
B. The Patentable Subject Matter Requirement as Applied to  
Processes and Methods 
Just as a patent can be obtained on an invention that is a physical prod-
uct, inventors can also obtain patents on methods or processes, including the 
method or process by which a physical product is created or transformed.48 
Although courts have not developed a clear-cut test to assess whether meth-
                                                                                                                           
 42 See generally David E. Adelman, A Fallacy of the Commons in Biotech Patent Policy, 20 
BERKELEY TECH. L.J. 1021 (2005) (arguing that limiting access to tools that are widely used to 
carry out various scientific research methods through granting patents on those tools will hinder 
innovation and technological process). 
 43 See Chakrabarty, 447 U.S. at 309 (articulating the three judicial exclusions to patentable 
subject matter); Parker, 437 U.S. at 598 (“The line between a patentable ‘process’ and an un-
patentable ‘principle’ is not always clear. Both are ‘conception[s] of the mind, seen only by [their] 
effects when being executed or performed.’” (quoting Le Roy v. Tatham, 55 U.S. 156, 175 
(1852))); Gottschalk, 409 U.S. at 67 (explaining that although a law of nature cannot be patented, 
an invention may be patentable if it applies a law of nature “to a new and useful end” (quoting 
Funk Bros. Seed Co., 333 U.S. at 130)). 
 44 See 35 U.S.C. § 101; e.g., Association for Molecular Pathology v. Myriad Genetics, Inc., 
133 S. Ct. 2107, 2119 (2013) (finding cDNA to be patentable subject matter despite containing 
naturally occurring nucleotide sequences); Chakrabarty, 447 U.S. at 310 (finding a bacterium with 
exogenous genes encoding hydrogen degradation pathway components to be patentable subject 
matter); see also Parke-Davis & Co. v. H.K. Mulford 196 F. 496, 500 (2d Cir. 1912) (finding 
isolated adrenaline to be patentable subject matter). 
 45 See Myriad, 133 S. Ct. at 2119 (challenging patent claim directed to cDNA); U.S. Patent 
No. 7,514,258 (filed Apr. 7, 2009) (mammalian cultured inner cell mass cell culture using a quies-
cent cell as nuclear); U.S. Patent Application No. 09/255,233 (filed Feb. 22, 1999) (quiescent cell 
populations for nuclear transfer). 
 46 35 U.S.C. § 101; see Myriad, 133 S. Ct. at 2119 (finding cDNA to be patentable subject 
matter in spite of the fact that cDNA is composed of nucleotides, which are naturally occurring 
phenomena excluded from patentable subject matter); Funk Bros. Seed Co., 333 U.S. at 130 (ar-
ticulating three judicial patentable subject matter exclusions). 
 47 35 U.S.C. § 101; see Myriad, 133 S. Ct. at 2119 (finding cDNA, a sequence of naturally 
occurring nucleotides, not to be a natural phenomenon); Funk Bros. Seed Co., 333 U.S. at 130 
(outlining the three judicial exclusions without further elaborating on how to apply these exclu-
sions). 
 48 35 U.S.C. § 101. One of the four categories of patentable subject matter under § 101 is 
processes. Id. 
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ods patents are patentable subject matter, several previous decisions provide 
guidance on this issue.49 In 2008, in In re Bilski, the United States Court of 
Appeals for the Federal Circuit articulated a standard to determine whether a 
method is patentable subject matter, known as the machine-or-transformation 
test.50 According to this standard, an invention is patentable subject matter if 
the invention is (1) tied to a particular machine or apparatus, or (2) it trans-
forms a particular article into a different state or thing.51 
In 2010, in Bilski v. Kappos, the U.S. Supreme Court diluted the Fed-
eral Circuit machine-or-transformation test, changing it from a test to an 
investigative tool.52 The outcome of the machine or transformation test, ac-
cording to the Court, correlates with, but does not indicate, the presence of 
patentable subject matter.53 
C. The Invention of iPS Cells 
Pluripotent stem cells are cells that can differentiate into nearly any 
type of bodily, or somatic, cell.54 These cells arise in the human embryo at a 
very early stage of development, only a few days following the fertilization 
of an egg cell.55 Scientific researches have used the innate differentiating 
                                                                                                                           
 49 See In re Bilski, 545 F.3d 943, 954 (Fed. Cir. 2008) (en banc) (establishing the machine-or-
transformation test to determine patentability of methods), aff’d, Bilski v. Kappos, 561 U.S. 593 
(2010) (rejecting machine-or-transformation test as the sole test for determining patentability of 
methods); see also Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336, 1349 
(Fed. Cir. 2009) (applying the machine-or-transformation test to upheld a patent on a method for 
administering a drug), vacated, 561 U.S. 1040 (2010). 
 50 In re Bilski, 545 F.3d at 954 (holding claim directed to hedging risk to be invalid); see 
Matthew Moore, In re Bilski and the “Machine-or-Transformation” Test: Receding Boundaries 
for Patent-Eligible Subject Matter, DUKE L. & TECH. REV. 005, at ¶¶ 8–12 (2010) (summarizing 
the Federal Circuit’s explanation of the machine-or-transformation test and explaining the types of 
transformations that would be considered sufficient to satisfy the patentable subject matter re-
quirement). 
 51 In re Bilski, 545 F.3d at 954. In 2009, the Federal Circuit decided Prometheus Laborato-
ries, Inc. v. Mayo Collaborative Services and utilized the machine-or-transformation test set out in 
Bilski. See Prometheus Laboratories, 581 F.3d at 1349; In re Bilski, 545 F.3d at 954. In Prome-
theus Laboratories, the defendant held a patent on a method for administering a drug. See 628 
F.3d 1347, 1349–50 (on remand from 561 U.S. 1040). The method involved measuring the level 
of metabolites of the drug in the bloodstream and increasing or decreasing the administered dose 
of the drug accordingly. See id. The Federal Circuit loosely applied the machine-or-transformation 
test set forth in In re Bilski and upheld the patent, stating that because the method involved a phys-
ical transformation, it therefore constituted patentable subject matter. See id. at 1355. 
 52 See Bilski, 561 U.S. at 604; Mark A. Lemley et al, Life After Bilski, 63 STAN. L. REV. 
1315, 1315 (2011) (describing the machine-or-transformation test as a “presumptive starting point 
that threatens to effectively become mandatory”). The U.S. Supreme Court, however, upheld the 
invalidity of the patents at issue. See Bilski, 561 U.S. at 604. 
 53 See Bilski, 561 U.S. at 604; Takahashi et al. 2007, supra note 11, at 861. 
 54 See Murnaghan, supra note 2. 
55 See id. In order to understand the origin of embryonic stem cells, it is essential to consider the 
first steps of embryonic development. See id. After an egg is fertilized by a sperm, a single cell re-
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ability of pluripotent stem cells to develop treatments for certain degenera-
tive diseases.56 When exposed to the right conditions, pluripotent stem cells 
can develop into healthy specialized cells that replace diseased cells and 
tissues.57 In addition, as an alternative to testing drugs on animals, human 
pluripotent stem cells can be used in initial drug testing.58 Drugs that are well 
tolerated by the cells can then progress to testing in animals and humans.59 
Prior to the invention of iPS cells, embryonic stem cells (“ESCs”) 
were arguably better suited for laboratory work than adult stem cells due to 
their ability to survive for longer durations in a laboratory and to differenti-
ate into more different types of cells.60 Despite the many applications and 
enormous potential benefits of stem cells in scientific research and medi-
cine, embryonic stem cells have been at the center of political and ethical 
debate for over two decades.61 The ESCs used for laboratory research are 
harvested from embryos originally created for reproductive purposes 
through in vitro fertilization.62 In order to harvest stem cells, scientists must 
extract cells from the blastocyst, thereby destroying the embryo.63 Because 
                                                                                                                           
sults. See id. This cell is totipotent, meaning it has the potential to differentiate into any type of cell. 
See Stem Cell Classification, BROWN UNIV., http://biomed.brown.edu/Courses/BI108/BI108_2002_
Groups/pancstems/stemcell/stemcellsclassversatility.htm [http://perma.cc/NZ26-TJYQ]. The original 
cell then divides several times into totipotent cells that are exact copies of the original. See id. Three 
to five days after fertilization, the totipotent cells begin to form a blastocyst, a cluster of cells that will 
eventually form most organs and tissues. See Murnaghan, supra note 2. It is these blastocyst cells that 
are pluripotent. See id. 
 56 See Murnaghan, supra note 2; Stem Cell Classification, supra note 55. 
 57 See Stem Cell Classification, supra note 55. Potential beneficiaries of stem cell regenerative 
treatment include individuals with severe burns, heart disease, spinal cord injuries, diabetes, Alz-
heimer’s, or Parkinson’s disease. See id.; Potential Uses, supra note 4. 
 58 See Murnaghan, supra note 2. 
 59 See id. Until 2006, scientists primarily worked with two types of stem cells: embryonic 
stem cells and adult stem cells. See What Are the Similarities and Differences Between Embryonic 
and Adult Stem Cells?, NAT’L INSTS. OF HEALTH (Mar. 3, 2015), http://stemcells.nih.gov/info/
basics/pages/basics5.aspx [http://perma.cc/ZYE7-6ESQ]. 
 60 See Murnaghan, supra note 2. 
 61 See Robertson, supra note 9, at 191. 
 62 What Are Embryonic Stem Cells?, NAT’L INSTS. OF HEALTH (Mar. 4, 2015), http://stem
cells.nih.gov/info/basics/pages/basics3.aspx [http://perma.cc/9SZV-ZUQ4]. When a couple that 
has pursued in vitro fertilization decides that they have completed their family and the remain-
ing embryos are no longer needed for their original purpose, the donor has the option to donate 
the embryos for research. Myths and Misconceptions About Stem Cell Research, CAL. INST. 
FOR REGENERATIVE MED., http://www.cirm.ca.gov/our-progress/myths-and-misconceptions-
about-stem-cell-research [http://perma.cc/WTB6-MM4Z] [hereinafter Myths and Misconcep-
tions]. Individuals who have elected to pursue in vitro fertilization have several options regard-
ing what to do with the remaining embryos once they have elected not to have more children. 
Id. One such option is to elect to store the embryos indefinitely at the couple’s own expense. Id. 
The cost of storing embryos, however, is very high. Id. The embryos can also be given to an-
other infertile couple. Id. The two remaining options are to discard the excess embryos or to 
donate them for cell research. Id. Both of these options entail destroying the embryo. See id. 
 63 See Myths and Misconceptions, supra note 62. 
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the destruction of any embryo raises ethical questions, the use of ESCs in 
order to better understand and treat certain diseases has been the subject of 
intense debate.64 Consequentially, the level of federal funding devoted to 
stem cell research since 1998 has been sporadic, which has slowed progress 
in developing stem cell-based treatments.65 
Recently, scientists at the University of Kyoto developed a new tech-
nology called induced pluripotent stem cells (“iPS cells”), which could 
eventually render the embryonic stem cell debate irrelevant by eliminating 
the need to harvest stem cells from embryos.66 In 2007, Dr. Shinya Yama-
naka of the University of Kyoto developed a method to genetically repro-
gram human adult somatic cells to return them to a stem cell-like state.67 
Essentially, Dr. Yamanaka found a way to create stem cells, which he called 
iPS cells, from skin cells.68 He did this by identifying four genes called 
                                                                                                                           
 64 See Robertson, supra note 9, at 191; An Overview of Stem Cell Research, supra note 6 (“We 
must not sacrifice one class of human beings (the embryonic) to benefit another (those suffering from 
serious illness).”); Myths and Misconceptions, supra note 62; Obama Overturns Bush Policy on Stem 
Cells, CNN (Mar. 9, 2009), http://www.cnn.com/2009/POLITICS/03/09/obama.stem.cells/index.
html [http://perma.cc/UX9R-JJPN] (discussing President Obama’s stance on embryonic stem cell 
research, including his statement that “we have been given the capacity and will to pursue this re-
search—and the humanity and conscience to do so responsibly”). 
 65 See Robertson, supra note 9, at 191. 
 66 See Takahashi et al. 2007, supra note 11, at 861. 
 67 See id. In 2006, prior to developing human iPS cells, Dr. Yamanaka published a method for 
reprogramming skin cells, or fibroblasts, from mice to return them to a stem cell-like state. See 
Takahashi et al. 2006, supra note 11, at 663. To do so, Dr. Yamanaka identified 24 genes in mice 
known to be important for cellular development. See id. He then forced fibroblasts to express 
different combinations of these 24 genes. See id. at 664–65. This was done by engineering retrovi-
ruses to insert various combinations of these 24 genes into the mouse genome. See id. He found 
that when 4 genes called Oct3/4, Sox2, Klf4, and c-Myc were introduced in combination, the 
fibroblast was reprogrammed to resemble an embryonic cell. See id. at 666. The forced expression 
of those 4 genes essentially caused a skin cell to become a cell resembling a stem cell. See id. 
 68 See Takahashi et al. 2007, supra note 11, at 861. Before examining how iPS cells were 
developed, it is important to understand how stem cells differ genetically from other types of bodi-
ly cells. See id.; Gene Expression, NATURE EDUC., http://www.nature.com/scitable/topicpage/
gene-expression-14121669 [http://perma.cc/UY32-56YB]. Each cell in the human body generally 
has the same genetic content. See Barry Starr, DNA Basics, STANFORD AT THE TECH: UNDER-
STANDING GENETICS, http://genetics.thetech.org/ask/ask4 [http://perma.cc/694U-8UER]. Skin 
cells, heart muscle cells, and liver cells, for example, have the same DNA. See id. What makes 
these cells different is that different genes are “turned on,” or expressed, in each cell type. See id. 
When a gene is expressed, a certain protein is in turn produced, which allows the cell to perform 
its function. See id. Genes encoding the protein hemoglobin, for example, need to be expressed in 
red blood cells, as hemoglobin is involved in carrying oxygen to cells. See id. In contrast, these 
same genes encoding hemoglobin are “turned off,” or silenced, in cells in the eye because oxygen 
transport is not a function of eye cells. See id. The combination of genes that are turned on and off 
is referred to as a cell’s gene expression pattern. See John P.T. Higgins, et al., Gene Expression 
Patterns in Renal Cell Carcinoma Assessed by Complementary DNA Microarray, 162 AM. J. 
PATHOLOGY 925, 925 (2003). Just as muscle cells and liver cells possess certain characteristics 
based on their gene expression pattern, the ability of a pluripotent stem cell to differentiate into a 
somatic cell is also attributed to its gene expression pattern. See Starr, supra. That is, the genes 
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Oct3/4, Sox2, Klf4, and c-Myc that are important for maintaining the prop-
erties of a stem cell.69 These genes were subsequently inserted into a skin 
cell, or fibroblast, using a genetically engineered virus.70 The resulting iPS 
cells demonstrated an ability to differentiate into many types of somatic 
cells.71 Because of their stem cell-like character, iPS cells could effectively 
end the embryonic stem cell debate, as scientists would no longer need to 
harvest embryonic cells in order to develop stem cell therapies.72 
                                                                                                                           
that are expressed in a stem cell enable the stem cell to become almost any cell in the body under 
the right circumstances. See id. Dr. Yamanaka’s goal was to determine what combination of ex-
pressed genes enables the stem cell to maintain its pluripotent state. See generally Baker, supra 
note 35 (explaining the techniques by which teams led by Dr. Yamanaka and Dr. James Thomson 
reprogrammed fibroblast cells). In other words, he sought to determine which genes need to be 
“turned on” in order for a cell to be a stem cell. See Takahashi et al. 2007, supra note 11, at 861; 
Takahashi et al. 2006, supra note 11, at 663. According to Dr. Yamanaka’s logic, if a skin cell, for 
example, could be forced to express the genes that stem cells typically express, the skin cell would 
then become a stem cell. See Takahashi et al. 2007, supra note 11, at 861; Takahashi et al. 2006, 
supra note 11, at 663. This process of forcing cells to express certain genes is called cellular re-
programming. See Takahashi et al. 2007, supra note 11, at 861; Takahashi et al. 2006, supra note 
11, at 673. 
 69 See Takahashi et al. 2007, supra note 11, at 861. 
 70 See id. at 863. A virus is essentially a piece of DNA encapsulated in a protein shell. How 
Are Genes Engineered?, PHYSICIANS AND SCIENTISTS FOR RESPONSIBLE APPLICATION OF SCI. 
AND TECH., http://www.psrast.org/whisge.htm [http://perma.cc/QL6U-89VC]. Viruses have the 
capability of injecting their genetic material into cells. See J. Stern Carter, Viruses, UNIV. OF CIN-
CINNATI AT CLERMONT DEP’T OF BIOLOGY (Jan. 16, 2014), http://biology.clc.uc.edu/courses/bio
106/viruses.htm [http://perma.cc/DJK3-QSF5]. The cells then produce the proteins that the viral 
genes encode. See id. In the method described in Dr. Takahashi and colleagues’ 2006 publication, 
the harmful retroviral genes were removed from the viral protein shell, and Oct3/4, Sox2, Klf4, 
and c-Myc were inserted into the virus. See Takahashi et al. 2006, supra note 11, at 664–65; A.G. 
Uren et al., Retroviral Insertional Mutagenesis: Past, Present, and Future, 24 ONCOGENE 7656, 
7656 (2005). This process is called retroviral gene therapy. See Donald S. Anson, The Use of Ret-
roviral Vectors—What Are the Risks? A Review of Retroviral Pathogenesis and Its Relevance to 
Retroviral Vector-Mediated Gene Delivery, 2:9 GENETIC VACCINES & THERAPY (2004), http://
www.gvt-journal.com/content/pdf/1479-0556-2-9.pdf [http://perma.cc/XEQ9-HW4N]. 
 71 See Takahashi et al. 2007, supra note 11, at 863–65. The cells were left to grow in culture 
for eight days, and it was observed that the cells began to show similar gene expression patterns as 
other types of somatic cells, including heart muscle cells and neurons. See id. This result suggest-
ed that Dr. Yamanaka’s iPS cells had the potential to differentiate into various types of somatic 
cells and had thereby acquired stem cell character. See id. 
 72 See id. at 861. In 2012, Dr. Yamanaka won the Nobel Prize in Physiology or Medicine for 
the development of human iPS cells. Shinya Yamanaka—Facts, THE NOBEL MUSEUM, http://
www.nobelprize.org/nobel_prizes/medicine/laureates/2012/yamanaka-facts.html [http://perma.cc/
QX23-8JCN]. Nearly concurrently in 2007, Dr. James Thomson and his colleagues at the Univer-
sity of Wisconsin published a similar method for developing iPS cells. See Junying Yu et al., In-
duced Pluripotent Stem Cell Lines Derived from Human Somatic Cells, 318 SCI. 1917, 1917 
(2007). Instead of inducing the expression of Klf4 and c-Myc in fibroblasts, Dr. Thomson induced 
the expression of the Nanog and Lin28 genes along with Oct3/4 and Sox2. Id. Like the cells de-
veloped by Dr. Yamanaka, the cells developed by Dr. Thomson also behaved like ESCs in cell 
culture and exhibited gene expression patterns of different somatic cell types, which suggested 
that Dr. Thomson’s iPS cells were pluripotent. Id. Thomson’s findings that cells could be repro-
grammed without the insertion of c-Myc and Klf4 was significant because c-Myc and Klf4 are 
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In the past eight years since Dr. Yamanaka’s discovery, the United 
States Patent and Trademark Office (“USPTO”) has issued over 100 patents 
related to iPS cell technologies.73 The subject matter claimed in these pa-
tents is directed toward several categories of technology related to iPS cells, 
including methods to develop human iPS cells from somatic cells, products 
comprising iPS cells, including iPS cells produced by various claimed 
methods, and nuclear reprogramming factors.74 The term “nuclear repro-
gramming factor” in the context of existing patents refers to a virus contain-
ing a certain combination of genes that are inserted into the cell and thereaf-
ter expressed, which ultimately results in somatic cell reprogramming.75 
As more scientists begin to use iPS cells as a research tool and de-
velop medical treatments based on this patented technology, it is very pos-
sible that the validity of many of these patents will eventually be chal-
lenged.76 The current statutes and case law governing the patentability 
requirements make unclear whether iPS cell technologies would be pa-
tentable.77 Although it can be argued that iPS cells are a natural phenome-
non because they resemble naturally occurring pluripotent stem cells, they 
                                                                                                                           
oncogenes, meaning that their insertion into the cellular genome can cause cancer. See Baker, 
supra note 35; C.E. Pasi et al., Genomic Instability in Induced Stem Cells, 18(5) CELL DEATH AND 
DIFFERENTIATION 745, 745 (2011). 
 73 U.S. Patent Full-Text and Image Database, U.S. PATENT & TRADEMARK OFFICE, http://
patft.uspto.gov/netahtml/PTO/search-bool.html (enter text “induced pluripotent stem cell” with 
quotations in Term 1 field, press “search”). 
 74 U.S. Patent No. 8,048,999 (issued Nov. 1, 2011); Bilyana P. Georgieva & Jane M. Love, 
Human Induced Pluripotent Stem Cells: A Review of the U.S. Patent Landscape, 5 REGENERA-
TIVE MED. 581, 581 (2010). See generally K. Triller Vrtovec & B. Vrtovec, Patent Eligibility of 
Induced Pluripotent Stem Cell Theranostics, 93 CLINICAL PHARMACOLOGY & THERAPEUTICS 
318, 319 (2013) (listing patents granted on iPS cell technologies in the United States). Dr. Yama-
naka filed three patent applications in the United States on December 13, 2005, claiming: nuclear 
reprogramming factors comprising different combinations of the genes Oct3/4, Sox2, Klf4, and c-
Myc; methods of preparing iPS cells through nuclear reprogramming; and a method of inducing 
differentiation of iPS cells. Brenda Simon et al., Pluripotent Patents Make Prime Time: An Analy-
sis of the Emerging Landscape, 28 NATURE BIOTECHNOLOGY 557, 559 (2010). Seven U.S. pa-
tents relating to iPS cell technologies were granted to Kyoto University in 2011 and 2012. Vrtovec 
& Vrtovec, supra, at 319. Dr. James Thomson was granted a U.S. patent in March of 2012, which 
claims a method of creating a population of primate pluripotent neural stem cells from iPS cells. 
U.S. Patent No. 8,133,731 (issued Mar. 13, 2012); Simon et al., supra, at 559. In March of 2010, a 
patent was granted to Rudolf Jaenisch claiming a somatic cell comprising in its genome a pluripo-
tency gene, wherein the pluripotency gene is a gene that is expressed in a pluripotent embryonic 
cell, is required for the pluripotency of the embryonic stem cell, and is down-regulated as the 
embryonic stem cell differentiates. U.S. Patent No. 7,682,828 (issued Mar. 23, 2010). 
 75 ’999 Patent. 
 76 See Paul Knoepfler, Putting the IP in iPS Cells: A Patent War Looming?, KNOEPFLER LAB 
STEM CELL BLOG (May 13, 2013), http://www.ipscell.com/2013/05/putting-the-ip-in-ips-cells-
patent-war-looming/ [http://perma.cc/7WRS-4DMT] (discussing a filed complaint challenging 
patent claims related to iPS cell technologies). 
 77 See infra notes 80–122 and accompanying text. 
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are also a synthetic creation made in a laboratory.78 Because iPS cell lines 
do not fit neatly within a judicial exclusion to patentable subject matter, a 
challenge to an iPS cell patent would present a particularly unique chal-
lenge to courts.79 
II. APPLICATION OF THE PATENTABLE SUBJECT MATTER REQUIREMENT IN 
LIFE SCIENCES 
Although no bright-line standard has been developed to assess whether 
an invention in the life sciences field is patentable subject matter, the Federal 
Circuit and the U.S. Supreme Court have issued a few crucial decisions that 
provide guidance as to when an invention that is derived from a naturally oc-
curring product is considered patentable subject matter.80 Section A will dis-
cuss the early applications of patentable subject matter in life sciences.81 Sec-
tion B will discuss will discuss how the U.S. Supreme Court applied the pa-
tentable subject matter requirement to DNA claims in Association for Molec-
ular Pathology v. Myriad Genetics, Inc.82 Section C will discuss the Interim 
Guidance on Patent Subject Matter Eligibility issued by the United States 
Patent and Trademark Office (“USPTO”) in December, 2014.83 
A. Applications of Patentable Subject Matter in Life Sciences Pre-Myriad 
In 1911 in Parke-Davis & Co. v. H.K. Mulford Co., the United States 
District Court for the Southern District of New York decided one of the first 
major cases relating to biotechnology as patentable subject matter.84 Judge 
Learned Hand upheld the validity of a patent on a purified and isolated form 
of adrenaline based upon certain structural differences between the purified 
and naturally occurring forms of adrenaline.85 The notion that a structural 
distinction between an original product and a purified product is sufficient 
                                                                                                                           
 78 See Takahashi et al. 2007, supra note 11, at 862 (explaining that iPS cells are composed of 
a human fibroblast and four reprogramming factors). 
 79 See 35 U.S.C. § 101; Funk Bros. Seed Co., 333 U.S. at 130 (articulating the three judicial 
exclusions to patentable subject matter); Takahashi et al. 2007, supra note 11, at 862 (explaining 
the method by which iPS cells were created by Dr. Yamanaka’s laboratory). 
 80 See infra notes 84–122 and accompanying text. 
 81 See infra notes 84–94 and accompanying text. 
 82 See infra notes 95–103 and accompanying text. 
 83 See infra notes 104–122 and accompanying text. 
 84 Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911), aff’d in part, 
rev’d in part, 196 F. 496 (2d Cir. 1912) (addressing novelty, not patentable subject matter). 
 85 Id. The court concluded that the patented purified extract was not, in fact, different from the 
prior art “only for a degree of purity,” but rather was a different chemical substance from that 
found in the prior art. Id. at 114–15 (discussing how no one had ever isolated a substance pro-
duced by the adrenal glands that was not in salt form and that the claimed base form of adrenaline 
was an original production of the patentee). 
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to uphold a patent was reinforced in 1938 by the United States Court of 
Customs and Patent Appeals, in In re Merz, wherein the Court of Customs 
and Patent Appeals ruled that if the purified product differs from the origi-
nal not only in degree but in kind, it may be patentable.86 
Nearly seventy years later in 1980, in Diamond v. Chakrabarty, the 
U.S. Supreme Court held that a bacterium with an inserted plasmid contain-
ing genes that are not naturally occurring in the plasmid is patentable sub-
ject matter.87 Prior to Chakrabarty, it was generally understood that living 
things were not patentable subject matter.88 Here, the Court emphasized that 
because the bacterium contained inserted genetic material that was not na-
tive to the bacterium, it was a non-natural manufacture or composition of 
matter and a product of human ingenuity.89 
In Chakrabarty, the patent examiner initially rejected the petitioner’s 
claims to the bacterium, stating that the bacterium did not constitute patenta-
ble subject matter on two grounds: 1) that bacteria are products of nature, and 
2) that bacteria are living things.90 The U.S. Supreme Court rejected both of 
these grounds and found the bacterium to be patentable subject matter, rea-
soning that the petitioner’s new bacterium had markedly different characteris-
tics from any organism found in nature, and the invented bacterium, accord-
ing to the Court, had the potential for significant practical utility.91 
The broad language that the Court used in Chakrabarty has made its 
logic difficult to apply to other life sciences inventions.92 The Court stated 
                                                                                                                           
 86 In re Merz, 97 F.2d 599, 601 (C.C.P.A. 1938) (finding a purified substance with a greater 
degree of purity than any product previously produced to be patentable subject matter). 
 87 Diamond v. Chakrabarty, 447 U.S. 303, 309–10 (1980); Anna Lumelsky, Diamond v. 
Chakrabarty: Gauging Congress’s Response to Dynamic Statutory Interpretation by the Supreme 
Court, 39 U.S.F. L. REV. 641, 643–48 (2005) (discussing the Supreme Court’s interpretation of 35 
U.S.C. § 101 in Chakrabarty). Plasmids are units of genetic material physically separate from the 
bacterium’s chromosomes. Chakrabarty, 477 U.S. at 310 n.1. The patentee discovered a process 
by which four plasmids could be transferred to a Pseudomonas bacterium. Id. The resulting bacte-
rium possessed the ability to degrade oil. Id. 
 88 Chakrabarty, 447 U.S. at 309–10; Smith, supra note 38, at 117. 
 89 Chakrabarty, 447 U.S. at 309–10. In his dissent, Justice Brennan stated that § 101 does not 
include living organisms. Id. at 320 (Brennan, J., dissenting); see also 35 U.S.C. § 101 (2012). He 
reasoned that because Congress created separate statutes to render agricultural inventions patenta-
ble, the lack of legislation governing the patentability of bacteria is indicative of Congress’s intent 
to exclude bacteria from patentable subject matter. Chakrabarty, 447 U.S. at 320 (Brennan, J., 
dissenting).  
 90 See Chakrabarty, 447 U.S. at 306. 
 91 See id. at 310 (explaining that because the patentee’s bacterium possessed “markedly dif-
ferent characteristics” than any found in nature, it is patentable subject matter). 
 92 See id.; Brent J. Jensen, Live, Human-Made Bacteria as Patentable Subject Matter Under 
35 U.S.C. § 101: Diamond v. Chakrabarty, 1980 BYU L. REV. 705, 712 (arguing that developing 
the markedly different characteristics test was unnecessary because Chakrabarty’s bacterium, 
which, according to the author, was more practically useful than the unmodified bacterium, fit into 
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that the bacterium at issue in Chakrabarty did not share characteristics with 
any bacterium found in nature.93 The Court did not clarify, however, wheth-
er the bacterium at issue would have been patentable subject matter had it 
only possessed characteristics that were markedly different from the bacte-
rium from which it was derived, and not from all bacteria found in nature.94 
B. The Patentable Subject Matter Requirement as Applied to DNA in 
Association for Molecular Pathology v. Myriad 
In 2013, in Association for Molecular Pathology v. Myriad Genetics, 
Inc., the U.S. Supreme Court was faced with the question of whether a puri-
fied and isolated substance constitutes patentable subject matter.95 In Myri-
ad, the defendant offered diagnostic tests for mutations in the BRCA1 and 
BRCA2 genes.96 Such mutations put women at an exceptionally high risk 
for breast and ovarian cancer.97 Myriad held patents claiming 1) the se-
quence of the BRCA1 and BRCA2 genes, and 2) the complementary DNA 
(“cDNA”) of the BRCA1 and BRCA2 genes.98 
                                                                                                                           
the definition of “manufacture” set out in 35 U.S.C. § 101); Smith, supra note 38 (explaining that 
Chakrabarty does not make clear whether iPS cell technologies would be patentable). 
 93 Chakrabarty, 447 U.S. at 310. 
 94 See id. 
 95 See Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2113 
(2013); Tup Ingram, Association for Molecular Pathology v. Myriad Genetics, Inc.: The Product 
of Nature Doctrine, Revisited, 29 BERKELEY TECH. L.J. 385, 387 (2014) (describing the potential 
implications of the Myriad ruling). 
 96 See Myriad, 133 S. Ct. at 2112; Sarah Elizabeth Hagan, DNA Real Estate: The Myriad 
Genetics Case and the Implications of Granting Patent Eligibility to Complementary DNA, 35 N. 
ILL. U. L. REV. 205, 221 (2014) (stating the concern that patents on genetic testing could increase 
the cost of such tests, which would harm both the public and the scientific community). 
 97 See Myriad, 133 S. Ct. at 2112–13. 
 98 See id. at 2113. Two steps must occur in order for a protein to be created from DNA: tran-
scription and translation. See Ribosomes, Transcription and Translation, NATURE EDUC., 
http://www.nature.com/scitable/topicpage/ribosomes-transcription-and-translation-14120660 [http://
perma.cc/AX7X-6WXK]. DNA is a double-stranded molecule containing the nucleotides adenine, 
guanine, thymine, and cytosine. See id. An adenine molecule on one strand of DNA will always 
bind to thymine on the opposite strand of DNA, and cytosine will always bind with guanine. See 
id. During transcription, the two stands of DNA are “unzipped,” and a complementary strand of 
RNA forms opposite each strand of DNA. See id. This complementary strand is called messenger 
RNA, or mRNA. See id. Once the mRNA is transcribed, it is processed. See id. Certain segments 
of the DNA are removed from the sequence, and the remaining segments, called exons, are spliced 
together. See Ribosomes, Transcription and Translation, supra. The cDNA, which was claimed in 
the defendant’s patent, is the DNA complement of processed mRNA. See Myriad, 133 S. Ct. at 
2111; cDNA Production, DAVIDSON COLL. DEP’T OF BIOLOGY (2002), http://www.bio.davidson.
edu/genomics/method/cDNAproduction.html [http://perma.cc/VDQ9-KC8S]. Although the genes 
contained in cDNA exist in nature, cDNA itself does not exist in nature and is a synthetic creation 
by scientists. See Myriad, 133 S. Ct. at 2119; DAVIDSON COLL. DEP’T OF BIOLOGY, supra. In 
Myriad, the Court reasoned that the BRCA genes contained in the form of cDNA can be patented 
because cDNA does not exist in nature. See 133 S. Ct. at 2119. 
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The Court held that the sequence of the BRCA genes was a naturally 
occurring segment and was not merely patent-eligible through isolation.99 
Justice Thomas explained that although Myriad had discovered the locus of 
the BRCA genes, Myriad did not do anything further to alter the genes.100 
The Court did, however, find that cDNA was patent eligible because it was 
a synthetic creation that did not occur in nature.101 To the Court, the princi-
pal difference between the cDNA and the naturally occurring gene, aside 
from cDNA not occurring in nature, was that only DNA contained introns, 
or “junk” regions of DNA that do not encode proteins and are eventually 
removed from the genetic transcript by the cell.102 Although cDNA contains 
the same functional genetic material as DNA, encodes the same proteins, 
and thereby essentially performs the same function, only cDNA, according 
to the Court, was patentable subject matter.103 
C. Interim Guidance by the USPTO 
On December 16, 2014, the USPTO released interim guidance on pa-
tent subject matter eligibility (“Guidance”).104 In the Guidance, the USPTO 
sets forth a three-step test for determining whether a product or process is 
patentable subject matter under § 101.105 
The first step requires an examiner to determine whether the claim is 
directed to a process, machine, manufacture, or composition of matter.106 If 
the claim is not so directed, the claim is not eligible subject matter under 
                                                                                                                           
 99 See Myriad, 133 S. Ct. at 2118. 
 100 See id. at 2116 (explaining that § 101 prevents the tools of innovation from being “tie[d] 
up”); id. at 2118 (noting how Myriad’s claims only listed the steps it took to discover gene se-
quences and did not “rely in any way on the chemical changes that result from the isolation of a 
particular section of DNA”). 
 101 See id. at 2119. 
 102 Id.; Reply Brief for Petitioners at 9–10, Myriad, 133 S. Ct. 2107 (No. 12-398), 2013 WL 
1850746, at *9 (explaining the difference between DNA and cDNA). 
 103 See Myriad, 113 S. Ct. at 2119; Reply Brief for Petitioners, supra note 102, at 9–10. 
 104 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. 74, 618 (Dec. 16, 
2014) (to be codified at 37 C.F.R. 1). This guidance became effective on December 16, 2014, and 
applies to all applications filed before, on, or after December 16, 2014. Id. The Guidance was 
prepared for use by USPTO personnel in determining subject matter eligibility under § 101 and 
was intended to supplement the guidance on preliminary examinations issued by the USPTO in 
June 2014. Id.; ANDREW H. HIRSCHFIELD, U.S. PATENT & TRADEMARK OFFICE, PRELIMINARY 
EXAMINATION INSTRUCTIONS IN VIEW OF THE SUPREME COURT DECISION IN ALICE CORPORA-
TION PTY. LTD. V. CLS BANK INTERNATIONAL, ET AL. (June 25, 2014), http://www.uspto.gov/sites/
default/files/patents/announce/alice_pec_25jun2014.pdf [http://perma.cc/V47L-TRW2]. This test 
does not constitute statutory law or binding precedent. Interim Guidance on Patent Subject Matter 
Eligibility, 79 Fed. Reg. at 74, 618. 
 105 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 622. 
 106 Id. Claims directed to these categories are patentable under 35 U.S.C. § 101. See id. 
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§ 101.107 The second step requires a determination as to whether the claim 
is directed to a law of nature, a natural phenomenon, or an abstract idea.108 
If the claim is not directed to one of these categories, the claim is eligible 
subject matter.109 If the claim is directed to one of these categories, the ex-
aminer should carry out the third step of the test, which requires the exam-
iner to determine whether the claim recites additional elements that amount 
to significantly more than the judicial exception.110 “Judicial exception” in 
the context of the third step refers to each of the three categories listed in 
the second step.111 
The Guidance sets out examples of considerations identified by the 
U.S. Supreme Court for determining whether a claim amounts to “signifi-
cantly more” than the judicial exception.112 Examples of limitations that 
qualify as “significantly more” include improvements to another technology 
or technical field, applying the judicial exception with a particular machine, 
effecting a transformation or reduction of a particular article to a different 
state or thing, and adding a specific limitation other than what is conven-
tional in the field.113 
Although the Guidance attempts to create a bright-line test for deter-
mining patentable subject matter, the test set out by the Guidelines does not 
clarify the uncertainty that has surrounded the patentable subject matter re-
quirement since the Myriad decision.114 For example, the Guidance seem-
                                                                                                                           
 107 35 U.S.C. § 101 (defining patent eligible subject matter); Interim Guidance on Patent Sub-
ject Matter Eligibility, 79 Fed. Reg. at 74, 622. 
 108 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 622 (explaining 
that courts are careful when deciding if a claim falls under a judicial exception “because at some 
level all inventions embody, use, reflect, rest upon, or apply a law of nature, natural phenomenon, 
or abstract idea”). 
 109 35 U.S.C. § 101 (defining patent eligible subject matter); Interim Guidance on Patent Sub-
ject Matter Eligibility, 79 Fed. Reg. at 74, 618. 
 110 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 622–23 (outlin-
ing the “markedly different characteristics analysis,” which “compares the nature-based product 
limitation to its naturally occurring counterpart in its natural state,” unless there is no naturally 
occurring counterpart, in which case “the comparison should be made to the closest naturally 
occurring counterpart”). 
 111 Id. Laws of nature, abstract ideas, and natural phenomenon are the three categories defined 
by courts to be unpatentable subject matter. See supra note 40 and accompanying text (outlining 
the three categories of judicial exclusions). 
 112 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 624. 
 113 Id. Examples of limitations that were found not to qualify as “significantly more” include 
mere instructions to implement an abstract idea on a computer, appending well-understood activi-
ties previously known to the industry, adding insignificant activity to the judicial exception, and 
generally linking the use of the judicial exception to a particular technological environment or 
field of use. Id. 
 114 Myriad, 133 S. Ct. at 2119 (finding cDNA to be patentable subject matter despite contain-
ing naturally occurring nucleotide sequences); Interim Guidance on Patent Subject Matter Eligibil-
ity, 79 Fed. Reg. at 74, 618. 
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ingly conflicts with Myriad with regard to whether the “markedly different 
characteristics” analysis should be applied.115 The Guidance indicates that 
nature-based products are subject to the markedly different characteristics 
analysis used to identify exceptions to the judicial exclusions.116 According 
to the markedly different characteristics test, a claim directed to a nature-
based product that does not exhibit markedly different characteristics from 
its naturally occurring counterpart falls into a judicial exclusion category 
and is not patentable subject matter unless it recites elements that amount to 
“significantly more” than the judicial exception.117 
The presence of the markedly different characteristics test in the Guid-
ance is seemingly inconsistent with prior case law.118 The markedly differ-
ent characteristics test was mentioned in Chakrabarty as dictum, but it was 
not used to determine whether the bacterium at issue constituted patentable 
subject matter.119 Furthermore, this test was not used or mentioned in Myri-
ad.120 If this test had been utilized, the court would have likely reached the 
opposite result with regard to the cDNA claims.121 Due to this inconsistency 
between the Guidance and prior precedent, the Guidance does not provide 
much clarity as to how the patentable subject matter requirement should be 
applied to inventions in the life sciences.122 
                                                                                                                           
 115 Myriad, 133 S. Ct. at 2119 (reasoning that because cDNA is a man-made construct, it is pa-
tentable subject matter in spite of the fact that it encodes the same proteins as naturally occurring 
DNA sequences); Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 618. 
 116 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 618. 
 117 Id. 
 118 Id.; see also Myriad, 133 S. Ct. at 2119 (finding a patent claim directed to cDNA is patent-
able subject matter without assessing whether such cDNA contained “markedly different charac-
teristics” to DNA found in nature); Chakrabarty, 447 U.S. at 309–10 (mentioning in dictum that 
the defendant’s bacterium, which was found to be patent eligible subject matter, possessed mark-
edly different characteristics from bacteria found in nature). 
 119 Chakrabarty, 447 U.S. at 310 (holding the bacterium at issue to be “not nature’s handi-
work” and therefore to be patentable subject matter). 
 120 Myriad, 133 S. Ct. at 2119 (explaining that “the lab technician unquestionably creates 
something new when cDNA is made” in response to petitioner’s argument that a cDNA nucleotide 
sequence is dictated by nature). 
 121 Id. Because there is very little difference between the function and properties of DNA and 
cDNA, the Court could have found that the cDNA contained no “markedly different” characteris-
tics from DNA, which is found in nature. Id. Following such logic, cDNA would be unpatentable 
under the test set out by the USPTO’s Guidance. Id.; Interim Guidance on Patent Subject Matter 
Eligibility, 79 Fed. Reg. at 74, 618. 
 122 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 74, 618. 
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III. THE PROBLEM OF PATENT THICKETS IN LIFE SCIENCES 
Courts have, in the past, considered arguments concerning patent thick-
ets in cases concerning patent invalidity.123 Patent thickets present a major 
problem in the life sciences field.124 A patent thicket is an overlapping set of 
intellectual property rights that requires an inventor to seek a license in order 
to commercialize an invention. 125  Cumulative innovation, or innovations 
which grow off existing innovations, is an economic asset.126 Patent thickets 
are viewed negatively because they make commercializing cumulative inno-
vation difficult, which discourages inventors from improving upon the inno-
vations of others.127 Section A discusses the Federal Circuit’s treatment of 
patent thickets in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.128 Section B 
discusses the U.S. Supreme Court’s more recent consideration of the issue in 
Association for Molecular Pathology v. Myriad Genetics, Inc.129 
A. The Federal Circuit’s Consideration of Patent Thickets in Ariad 
The U.S. Court of Appeals for the Federal Circuit’s 2010 decision in 
Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. marked one of the first cases 
in which the Federal Circuit considered arguments concerning the creation 
of patent thickets surrounding biochemical pathways.130 Although patenta-
ble subject matter was not at issue in Ariad, arguments made by the plaintiff 
concerning the dangers of patent thickets could also be relevant in a case in 
which iPS cell preparation methods are at issue.131 
                                                                                                                           
 123 See infra notes 130–148 and accompanying text (discussing how the U.S. Supreme Court 
and the Federal Circuit have considered patent thickets when evaluating whether an invention is 
patentable subject matter). 
 124 CARL SHAPIRO, INNOVATION POLICY AND THE ECONOMY 120 (Adam B. Jaffe et al. eds., 
2001), available at http://www.nber.org/chapters/c10778.pdf [http://perma.cc/J42L-XDZJ]. 
 125 Id. (defining a patent thicket as “a dense web of overlapping intellectual property rights 
that a company must hack its way through in order to actually commercialize new technology”). 
 126 Id. 
 127 Id. at 121 (arguing that the large number of patents in the United States hinders the com-
mercialization of new technologies because it requires innovators to pay patent-holders in order to 
utilize certain products, processes, and methods). 
 128 See infra notes 130–138 and accompanying text. 
 129 See infra notes 139–148 and accompanying text. 
 130 See Ariad Pharm., Inc. v. Eli Lilly & Co. (Ariad II), 598 F.3d 1336, 1340 (Fed. Cir. 2010); 
Defendant Eli Lilly and Company’s Opposition Claim Construction Brief at 15, Ariad Pharm., 
Inc. v. Eli Lilly & Co. (Ariad I), 529 F. Supp. 2d 106, 117 (D. Mass. 2007), aff’d in part, rev’d in 
part, 598 F.3d 1336 (Fed. Cir. 2010) (No. 02 CV 11280 RWZ), 2003 WL 24337596 (stating that 
Ariad had claimed in its patent all compounds that function to inhibit NF-kB). 
 131 See Opposition Claim Construction Brief, supra note 130, at 15 (explaining that the patent 
claims at issue were not limited to any particular compound containing any particular structure); 
Takahashi et al. 2007, supra note 11, at 862. 
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In Ariad, the defendant, Ariad, had created a molecule that reduced 
binding of the transcription factor NF-kB, which in turn reduces cytokine 
production.132 Ariad had claimed use of all substances that achieve the re-
sult of reducing binding of NF-kB to NF-kB recognition sites.133 At the dis-
trict court level, plaintiff Eli Lilly had argued that the cytokine production 
pathway in which NF-kB is involved is a natural phenomenon.134 Eli Lilly 
asserted that Ariad’s claim to all means of reducing NF-kB binding without 
naming the specific molecule that inhibits binding created a patent thicket 
surrounding the cytokine production pathway.135 
Judge Rader responded to Eli Lilly’s argument in his dissent.136 Judge 
Rader stated that Congress, and not the courts, is ultimately responsible for 
balancing upstream and downstream innovation.137 Although the court ulti-
mately did not find Eli Lilly’s argument to be persuasive, Ariad was one of 
the first cases to bring attention to the potentially problematic effects that 
patent thickets surrounding biochemical pathways or processes could have 
on technological advancement in the biological sciences.138 
B. The Supreme Court’s Consideration of Patent Thickets in Myriad 
The U.S. Supreme Court has also considered the issue of patent thick-
ets.139 In 2013, in Association for Molecular Pathology v. Myriad Genetics, 
Inc., the U.S. Supreme Court heard arguments regarding the need to prevent 
the creation of patent thickets so as not to hinder biological research.140 Pe-
                                                                                                                           
 132 See Ariad II, 598 F.3d at 1340 (finding the claim at issue that was directed to all embodi-
ments of NF-kB inhibitors to be patent ineligible). 
 133 See id. 
 134 Opposition Claim Construction Brief, supra note 130, at 15. 
 135 See id. That is, if a court were to find Ariad’s claims to be valid, there would be little room 
for innovation because virtually all methods of reducing NF-kB binding have already been 
claimed. See id.; Ken Garber, Patently Absurd?, 24 NATURE BIOTECHNOLOGY 737, 738 (2006) 
(explaining that a broad patent similar to Ariad’s patent that covers “upstream” research tools 
could lead to patent thickets). But see Jonathan E. Barbee, Innovation on the Cutting Edge of Ari-
ad: Reinventing the Written Description Requirement, 86 N.Y.U. L. REV. 1895, 1929 (2011) (ar-
guing that scholars should not be as concerned about patent thickets and noting that Ariad’s patent 
“was one of nearly one hundred” patents related to NF-kB). 
 136 See Ariad II, 598 F.3d at 1361 (Rader, J., dissenting in part). 
 137 See id. (explaining that § 101 already balances upstream and downstream innovation by 
setting forth the written description requirement, which requires patent applicants to provide “a 
written description of the invention”) (citing 35 U.S.C. § 112 (2012)). 
 138 See id. 
 139 See Ariad I, 529 F. Supp. 2d at 117; see also Association for Molecular Pathology v. Myri-
ad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013) (“[W]ithout [§ 101], there would be considerable 
danger that the grant of patents would ‘tie up’ the use of such tools and thereby ‘inhibit future 
innovation premised upon them.’”) (quoting Mayo Collaborative Servs. v. Prometheus Labs., Inc., 
132 S. Ct. 1289, 1293 (2012)). 
 140 See Myriad, 133 S. Ct. at 2116. 
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titioners argued that Myriad’s claim of DNA containing the BRCA1 and 
BRCA2 genes should be invalid because DNA is a naturally occurring 
product.141 The Court held the claim to be invalid, explaining that although 
Myriad had discovered the locus of the BRCA genes, Myriad did not do 
anything further to alter the genes.142 Accordingly, the BRCA genes were 
found not to be patentable subject matter.143 Justice Thomas emphasized in 
his opinion that the very purpose of patents is to promote creation, and by 
“tying up” natural phenomena, which are the basic tools of scientific re-
search, the patent system would inhibit future innovation premised upon 
such phenomena.144 
Although Myriad and Ariad differ in that only in Myriad was patenta-
ble subject matter at issue, both cases represent two contrasting ways in 
which courts have grappled with the issue of patent thickets in the life sci-
ences field.145 The fact that Myriad was decided recently in 2013 could 
suggest that courts are more willing than they were five years ago to con-
sider the effect of a validating decision on patent thickets in the biological 
field.146 The Myriad decision could also suggest that the Court’s view of 
what constitutes patentable subject matter is evolving to become more re-
strictive.147 Contrastingly, the Myriad decision could simply be an outlier, 
and future decisions could more closely resemble the approach taken in Ar-
                                                                                                                           
 141 See id.; Reply Brief for Petitioners, supra note 102, at 9–10 (explaining that Myriad’s 
proposed standard for § 101 would be “whether the composition is a result of ‘human interven-
tion’”). 
 142 See Myriad, 133 S. Ct. at 2118 (“Many of Myriad’s patent descriptions simply detail the 
iterative process of discovery by which Myriad narrowed the possible locations for the gene se-
quences that it sought . . . . [Myriad’s claims do not] rely in any way on the chemical changes that 
result from the isolation of a particular section of DNA.”). 
 143 See id. 
 144 See id. at 2116 (explaining § 101’s purpose as a preventative measure against patent thickets). 
Although the Court’s ruling arguably prevents patent thickets surrounding DNA, another concern is 
whether such a ruling will discourage genetic research. See Editorial, After DNA Patent Ruling, Con-
gress Must Encourage Genetic Research, WASH. POST (June 13, 2013), https://www.washington
post.com/opinions/after-dna-patent-ruling-congress-must-encourage-genetic-research/2013/06/13/c7a
86d98-d458-11e2-b05f-3ea3f0e7bb5a_story.html [https://perma.cc/47NT-DZVV] [hereinafter Con-
gress Must Encourage Genetic Research] (arguing that Congress must develop a better scheme by 
which the patent system can foster genetic research but still protect upstream research tools); Intellec-
tual Property and Genomics, NAT’L INSTS. OF HEALTH (Oct. 30, 2014), http://www.genome.gov/
19016590 [http://perma.cc/7K8D-6RKN] (stating that the National Institutes of Health and the Na-
tional Human Genome Research Institute were “very pleased” with the ruling in Ariad and believe 
that Ariad will promote progress in the field of genomic medicine). 
 145 See Myriad, 133 S. Ct. at 2116 (discussing the goal of keeping scientific research tools in 
the public domain); Ariad I, 529 F. Supp. 2d at 117 (explaining that the courts are not responsible 
for balancing upstream and downstream innovation). 
 146 See Myriad, 133 S. Ct. at 2116; Ariad I, 529 F. Supp. 2d at 117. 
 147 See Myriad, 133 S. Ct. at 2116 (disallowing patents on DNA sequences, despite their po-
tential to help scientists detect mutations). 
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iad, which seems to consider less carefully the possibility that a validating 
decision would create a patent thicket.148 
IV. NEW STANDARDS WITH WHICH TO EVALUATE PATENTABLE SUBJECT 
MATTER IN THE CONTEXT OF LIFE SCIENCES INVENTIONS AND METHODS 
Recent decisions related to the patentability of purified products, living 
organisms, and methods evidence the ongoing struggle of the courts to iden-
tify the boundaries of patentable subject matter, especially in the field of 
biotechnology.149 The lack of clear boundaries in this area leaves unclear 
whether induced pluripotent stem cells (“iPS cells”) and methods for pre-
paring iPS cells are in fact patentable.150 iPS cells are only one example of 
an invention within the life sciences that neither clearly meets the patenta-
ble subject matter requirement nor explicitly falls under the definition of 
“product of nature” in the context of 35 U.S.C. § 101.151 Many inventions in 
the life sciences field, like iPS cells, are derived from a product of nature, 
and researchers in this field have no clear way to anticipate whether such 
inventions will be patentable.152 
Developing a clearer standard with which to evaluate patentable sub-
ject matter in the context of the life sciences would not only assist inventors 
in anticipating whether their creations are patentable, but it would also as-
sist judges, who often have a limited scientific background, in assessing 
whether complex inventions fit under the broad categories of patentable 
                                                                                                                           
 148 See Myriad, 133 S. Ct. at 2116; Ariad I, 529 F. Supp. 2d at 117. 
 149 See supra notes 84–122 and accompanying text (explaining how courts have previously 
applied the patentable subject matter requirement to life sciences innovations); see also Alice 
Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2360 (2014). In 2014, in Alice Corp. Party 
Ltd. v. CLS Bank International, the U.S. Supreme Court once again confronted the issue of deter-
mining what constitutes patentable subject matter and again fell short of articulating a clear stand-
ard. See 134 S. Ct. at 2360. Although the Court emphasized that the machine-or-transformation 
test is still useful, the holding in Alice suggests that patent holders will need to show something 
beyond tying a law of nature, abstract idea, or physical phenomenon to a machine. See id. at 2357. 
 150 See Alice, 134 S. Ct. at 2357; Bilski v. Kappos, 561 U.S. 593, 603 (2010). 
 151 See 35 U.S.C. § 101 (2012); Josephine Johnston, Intellectual Property and Biomedicine, in 
FROM BIRTH TO DEATH AND BENCH TO CLINIC: THE HASTINGS CENTER BIOETHICS BRIEFING 
BOOK FOR JOURNALISTS, POLICYMAKERS, AND CAMPAIGNS 93, 93 (Mary Crowley ed., 2008), 
available at http://www.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/intellect
ual%20property%20chapter.pdf [http://perma.cc/M6GQ-FMSE] (discussing the rising number of 
patents related to “biomedical materials and processes, such as cell lines, and methods of replicat-
ing them, such as cloning”); What Will Happen to Biotech’s Patent Thickets After Myriad?, MICH. 
TELECOMMUNICATIONS & TECH. L. REV. BLOG (Oct. 21, 2014), http://mttlr.org/2014/10/21/what-
will-happen-to-biotechs-patent-thickets-after-myriad-and-prometheus/ [http://perma.cc/EXS4-D9
DC] (explaining that the patentability of iPS cells is uncertain following Association for Molecular 
Pathology v. Myriad Genetics, Inc.). 
 152 See supra notes 84–122 and accompanying text (explaining why there is no clear standard 
with which to determine whether an invention derived from a product of nature is patentable). 
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subject matter set out in § 101.153 Section A articulates a standard with 
which patentable subject matter can be evaluated in the context of life sci-
ences inventions.154 Section B articulates a standard with which methods 
patents can be evaluated.155 
A. Evaluating Patentable Subject Matter in the Context of the Life Sciences 
Using a Modified Chakrabarty Standard 
The U.S. Supreme Court’s 1980 decision in Diamond v. Chakrabarty 
provides the best starting point for determining how much an invention de-
rived from a product of nature must be altered in order to be considered a 
man-made invention for purposes of § 101.156 In Chakrabarty, the Court 
indicated in its analysis that the bacterium had characteristics that were 
“markedly different” from any existing bacterium.157 The Court also noted 
that the bacterium had the potential for significant utility.158 Although this 
language in Chakrabarty provides some direction as to what might consti-
tute a product of nature, courts have not employed this language as a strict 
standard for evaluating patentable subject matter.159 To promote clarity in 
this important area of the law, courts should adopt a more clear-cut standard 
to evaluate when inventions derived from products of nature are patentable 
under § 101.160 
                                                                                                                           
 153 See 35 U.S.C. § 101; Johnston, supra note 151, at 93 (acknowledging that Congress can 
develop new laws and courts can adopt practices that will both encourage innovation and prevent 
the patent system from hindering access to medical treatments). 
 154 See infra notes 156–196 and accompanying text. 
 155 See infra notes 197–207 and accompanying text. 
 156 Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980); Dan L. Burk & Mark A. Lemley, Is 
Patent Law Technology-Specific?, 17 BERKELEY TECH. L.J. 1155, 1173–83 (2002) (describing 
how courts have applied patent law to biotechnology in pre-2002 cases). 
 157 Chakrabarty, 447 U.S. at 310 (“[T]he patentee has produced a new bacterium with mark-
edly different characteristics from any found in nature and one having the potential for significant 
utility. His discovery is not nature’s handiwork, but his own; accordingly it is patentable subject 
matter under § 101.”). 
 158 See id. at 309–10 (noting that the claim at issue was “a nonnaturally occurring manufac-
ture or composition of matter—a product of human ingenuity ‘having a distinctive name, character 
[and] use’” and therefore should be patentable) (quoting Hartranft v. Wiegmann, 121 U.S. 609, 
615 (1887)). 
 159 See id. at 310. Although Justice Thomas quoted this language in Myriad, the Court in 
Myriad did not treat the possession of markedly different characteristics and the potential for sig-
nificant utility as distinct criteria that must be met in order for an invention to be considered pa-
tentable subject matter. See Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. 
Ct. 2107, 2117 (2013); Chakrabarty, 447 U.S. at 310. The Court also did not articulate a separate 
standard that must be met in order for an invention derived from a natural product to be consid-
ered patentable subject matter. Myriad, 133 S. Ct. at 2117; Chakrabarty, 447 U.S. at 310. 
 160 35 U.S.C. § 101; see supra notes 79–121 and accompanying text (describing the confusion 
surrounding the patentable subject matter requirement in the context of life sciences). 
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In order to assess whether a biological invention derived from a prod-
uct of nature is patentable subject matter, courts should assess: (1) whether 
the invention at issue possesses “markedly different characteristics” from 
the natural product from which it was derived; and (2) whether the inven-
tion possesses a practical utility, or combination of practical utilities, that 
does not exist in any product occurring in nature.161 Because this standard 
draws on the language used in Chakrabarty, it is referred to in this Note as 
the “modified Chakrabarty standard.”162 
It is important to note two key differences between the modified 
Chakrabarty standard and the language used in Chakrabarty.163 First, the 
Court in Chakrabarty indicated that the bacterium at issue possesses charac-
teristics that were “markedly different” than any bacterium found in nature, 
whereas according to the modified Chakrabarty standard, an invention must 
possess markedly different characteristics from the product of nature from 
which the invention is derived.164 Second, the Court in Chakrabarty indi-
cated that the bacterium at issue possessed the potential for significant utili-
ty.165 The modified Chakrabarty standard not only requires the invention to 
possess practical utility, but it also requires that the invention’s practical 
utility, or combination of practical utilities, not exist in another known 
product of nature.166 This criterion would be separate from the § 101 utility 
requirement.167  
Accordingly, section 1 addresses the rationale behind requiring that an 
invention possess a markedly different characteristic from the natural prod-
uct from which it was derived.168 Section 2 addresses why, under the modi-
fied Chakrabarty standard, an invention must possess a practical utility or 
                                                                                                                           
 161 See Chakrabarty, 447 U.S. at 310. The goal of this standard is not only to elucidate which 
inventions in the biotechnology field are patent-eligible, but also to prevent widely-used research 
tools from being the subject of a patent monopoly. See generally David E. Adelman, A Fallacy of 
the Commons in Biotech Patent Policy, 20 BERKELEY TECH. L.J. 1021 (2005) (arguing that limit-
ing access to scientific research tools through patent protection can hinder technological innova-
tion). 
 162 See Chakrabarty, 447 U.S. at 310 (finding a bacterium with characteristics “markedly 
different” from any found in nature to be patentable). 
 163 See id. 
 164 See id. 
 165 See id. It is unclear whether the Court intended to convey that merely meeting the utility 
requirement was evidence in support of an invention being patentable subject matter. See 35 
U.S.C. § 101; Chakrabarty, 447 U.S. at 310. 
 166 See Chakrabarty, 447 U.S. at 310. 
 167 See 35 U.S.C. § 101; Chakrabarty, 447 U.S. at 310; David B. Resnik, A Biotechnology 
Patent Pool: An Idea Whose Time Has Come?, J. PHIL., SCI. & L., vol. 3 (2003), http://jpsl.org/
archives/biotechnology-patent-pool-idea-whose-time-has-come/ [http://perma.cc/8UMR-2WY8] 
(discussing various approaches that have been proposed by scholars to prevent the formation of 
patent thickets in biotechnology). 
 168 See infra notes 170–186 and accompanying text. 
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combination of practical utilities that does not exist in any known product 
of nature.169 
1. An Invention Must Possess a “Markedly Different” Characteristic from 
the Natural Product from Which It Was Derived 
The modified Chakrabarty standard compares the invention to only the 
natural product from which it was derived for three principal reasons.170 
First, requiring that an invention possess a markedly different characteristic 
from all products of nature could prompt researchers to tailor their inven-
tions to comply with this requirement, which could compromise the effec-
tiveness of certain medical treatments or other biological inventions.171 The 
synthetic creation of products that resemble products found in nature is be-
coming increasingly common.172 In the case of iPS cells and of most cell 
lines maintained in laboratories, certain minor differences do exist between 
the laboratory cells and cells found in nature.173 Generally, however, the 
more similar a cell line maintained in a laboratory is to a cell line found in 
nature, the more useful that cell line is for scientific research.174 In the case 
of an iPS cell, for example, the more similar an iPS cell is to a naturally 
occurring embryonic stem cell, the more likely it will be able to differenti-
ate into nearly every type of human cell.175 
If a court were to set out a standard that a cell created in a laboratory 
must contain a certain degree of dissimilarity to all naturally occurring cells, 
scientists might purposefully try to create iPS cells that possess that degree of 
dissimilarity instead of trying to create cells that are as similar as possible to 
naturally occurring cells.176 Doing so would likely compromise the effective-
                                                                                                                           
 169 See infra notes 187–196 and accompanying text. 
 170 See infra notes 171–186 and accompanying text. 
 171 See Chakrabarty, 447 U.S. at 307 (noting that patent laws promote economic development 
by creating incentives for ingenuity through the use of exclusive rights). 
 172 See Johnston, supra note 151, at 93 (discussing the rise in the number of patents granted 
on biomedical materials and processes). 
 173 See Barbara S. Mallon et al., Comparison of the Molecular Profiles of Human Embryonic 
and Induced Pluripotent Stem Cells of Isogenic Origin, 12 STEM CELL RES. 376, 376 (2014) (dis-
cussing the results of a study that found embryonic stem cells and iPS cells possessed a similar 
methylation pattern and genetic expression pattern, which suggested that the two types of cells 
have a high degree of similarity); Takahashi et al. 2007, supra note 11, at 861. But see Kazim H. 
Narsinh et al., Comparison of Human Induced Pluripotent and Embryonic Stem Cells: Fraternal 
or Identical Twins?, 19 MOLECULAR THERAPY 635, 635 (2010) (explaining that iPS cells have 
varying differentiation propensities and do not always develop into the desired cell type). 
 174 See Robin Feldman & Deborah Furth, The Intellectual Property Landscape for iPS Cells, 
3 STAN. J.L. SCI. & POL’Y 16, 24 (2010) (explaining that improper reprogramming can hinder an 
iPS cell’s ability to differentiate into different types of cells and can result in teratoma formation). 
 175 See id. 
 176 Chakrabarty, 447 U.S. at 307 (explaining how scientists have an economic motivation to 
create patentable inventions). The goal and purpose of patent law, as articulated in Chakrabarty, is 
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ness of any medical treatments or diagnostic methods for which the iPS cells 
would be used.177 Cells that are intentionally created to be dissimilar to a cer-
tain degree to naturally occurring stem cells might not differentiate into other 
types of cells as readily or consistently, which could render medical treat-
ments or diagnostic tools derived from these cells less effective.178 
Second, the modified Chakrabarty standard assesses whether a mark-
edly different characteristic exists only between the invention and the prod-
uct from which it was derived because society should incentivize scientists 
to create inventions that mimic naturally-occurring biological products, for 
such inventions have substantial utility.179 Isolated insulin, for example, is 
essential to the management of Type I diabetes.180 Isolated adrenaline is 
critical in the treatment of cardiac arrest or anaphylaxis.181 Although insulin 
and adrenaline used therapeutically possess certain structural differences 
from naturally-occurring insulin and adrenaline, it is not always the case 
that a natural product created or isolated in a laboratory will be markedly 
                                                                                                                           
to drive inventiveness and research efforts. See id. If such laws will only protect inventiveness and 
research efforts that result in iPS cells that are similar to, but not as similar as possible to ESCs, 
such laws will drive research efforts to create iPS cells that are patent eligible subject matter but 
not necessarily optimal for use as a diagnostic tool and medical treatment. See id.; Feldman & 
Furth, supra note 174, at 24 (explaining the consequences of improper iPS cell reprogramming). 
 177 See Feldman & Furth, supra note 174, at 24. 
 178 See id; Narsinh et al., supra note 173, at 635 (finding significant variation in the differenti-
ation propensities of iPS cells and ESCs). But see Mallon et al., supra note 173, at 376 (finding no 
gene probe with expression that altered significantly between human iPS cells and ESCs). Regard-
less of policy interests in favor of or against a finding that iPS cells do contain markedly different 
characteristics from naturally occurring ESCs, a court would have difficulty examining the molec-
ular differences between iPS cells and ESCs because it is still very much under debate whether 
significant molecular difference exist between the two types of cells. See Narsinh et al., supra note 
173, at 635. But see Mallon et al., supra note 173, at 376 (finding that iPS cells and ESCs have 
highly similar genetic expression and methylation patterns). Because of the lack of definitive re-
search on the topic, a court would be likely to approach the issue of whether marked differences 
exist between iPS cells and ESCs by looking at the non-molecular differences between the cells, 
such as the fact that iPS cells can be obtained without harming human embryos. See Chakrabarty, 
447 U.S. at 310; Narsinh et al., supra note 173, at 635. But see Mallon et al., supra note 173, at 
376 (finding that iPS cells and ESCs possess a high degree of similarity). 
 179 See Chakrabarty, 447 U.S. at 307 (explaining the purpose of the patent system as an in-
centive for innovation); Paul Cole, USPTO Patent Eligibility Guidelines: A Topsy-Turvy Ap-
proach for Natural Products, IPWATCHDOG (Mar. 10, 2014), http://www.ipwatchdog.com/2014/
03/10/uspto-patent-eligibility-guidelines-natural-products/id=48451/ [http://perma.cc/D3NV-AASQ] 
(arguing that the Myriad decision creates uncertainty surrounding patents on biotechnology, which 
could, in turn, harm the economy). 
 180 See The Discovery of Insulin, NOBELPRIZE.ORG (Feb. 2009), http://www.nobelprize.org/
educational/medicine/insulin/discovery-insulin.html [http://perma.cc/SNV3-T9QB] (explaining the 
discovery and medical uses of insulin). 
 181 See Epinephrine, UNIV. OF DEL., http://www.udel.edu/chem/C465/senior/fall00/Performance1/
epinephrine.htm.html [http://perma.cc/UM5N-QXPD] (explaining the medical uses of epinephrine). 
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different than that which exists in nature.182 If there were a strict ban on pa-
tenting inventions that do not markedly differ from products of nature, there 
would not be as much incentive for scientists to isolate or create a com-
pound or cell that could be of enormous benefit to the public.183 
Finally, scientists’ capacity to identify genes and their function has vast-
ly expanded since the 1980s and the Court’s decision in Chakrabarty.184 Due 
to the technological progress that has been made, plaintiffs can more easily 
identify naturally occurring organisms that share characteristics with the in-
vention at issue.185 Therefore, requiring that an invention possess markedly 
different characteristics than any organism found in nature presents a greater 
challenge to patentability today than it did when Chakrabarty was decided.186 
2. The Invention Must Possess a Practical Utility or Combination of Practical 
Utilities That Does Not Exist in Any Known Product of Nature 
In order to safeguard against patent thickets on natural products, the 
modified Chakrabarty standard also requires that the invention possess a 
practical utility or combination of practical utilities that does not exist in 
any product of nature.187 If the invention possessed only as much practical 
utility as an existing natural product, there would be little or no public bene-
fit rendered by granting a patent on such an invention.188 There could, how-
                                                                                                                           
 182 See Narsinh et al., supra note 173, at 635 (finding significant variation in the differentia-
tion propensities of iPS cells and ESCs). But see Mallon et al., supra note 173, at 376 (finding no 
gene probe with expression that altered significantly between human iPS cells and ESCs). In the 
case of iPS cells or in the case of many types of cell lines maintained in a laboratory, there is often 
no markedly different characteristic, aside from differences in molecular markers, between the 
cells maintained in a lab and the cells as they exist in nature. See Narsinh et al., supra note 173, at 
635. But see Mallon et al., supra note 173, at 376. 
 183 See Johnston, supra note 151, at 85 (explaining the importance of patents and listing how 
patents “[a]ct as an incentive for biomedical research,” “[s]ecure funds to turn early discoveries 
into medical products,” “[e]nsure that knowledge is disclosed to the public,” and “[i]ncrease the 
chance that people will have access to . . . medical products they need”); Congress Must Encour-
age Genetic Research, supra note 144 (arguing that because the Myriad decision could discourage 
genetic research by denying scientists patents on genes used for diagnostic purposes, Congress 
should reexamine other sources of economic motivation for scientists to conduct such research). 
 184 See Chakrabarty, 447 U.S. at 307; P.C.Y. Woo et al., Then and Now: Use of 16S rDNA 
Sequencing for Bacterial Identification and Discovery of Novel Bacteria in Clinical Microbiology 
Laboratories, 14 CLINICAL MICROBIOLOGY & INFECTION 908, 908 (2008) (explaining how, since 
the 1990s, scientists’ ability to sequence DNA and identify genes has led to the discovery of novel 
bacteria). 
 185 See Chakrabarty, 447 U.S. at 307; Woo et al., supra note 184, at 908. 
 186 See Chakrabarty, 447 U.S. at 307; Woo et al., supra note 184, at 908. 
 187 See infra notes 188–196 and accompanying text (explaining how the modified Chakrabarty 
standard protects against patent thickets, or patent monopolies on technologies within a given field). 
 188 See Johnston, supra note 151, at 85 (explaining how the patent system incentivizes scien-
tific research and enables scientists to obtain the financial backing to further develop discoveries); 
William Hubbard, The Competitive Advantage of Weak Patents, 54 B.C. L. REV. 1909, 1910 
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ever, be consequences from granting a monopoly on a man-made product 
that is a derivative of a natural product.189 If a scientist, for example, sought 
a patent on a complementary DNA (“cDNA”) sequence and, unlike the 
BRCA cDNA in the 2013 U.S. Supreme Court case Association for Molecu-
lar Pathology v. Myriad Genetics, Inc., the cDNA sequence at issue had no 
practical utility as a diagnostic tool, the granting of a patent on such an in-
vention would render little public benefit.190 The patent could, however, 
force scientists to obtain licensing agreements to utilize certain cDNA se-
quences in the course of their research.191 By this logic, granting patents on 
certain inventions derived from natural products could slow the pace of sci-
entific research within certain fields.192 
Although the modified Chakrabarty standard would make clearer to sci-
entists when natural-product-derived inventions are and are not patentable, 
the standard is still sufficiently flexible to allow judges to interpret and apply 
the law as they see fit.193 The term “markedly different characteristic,” for 
example, in the context of the modified Chakrabarty standard, is not de-
fined.194 The standard also does not articulate the degree to which the practi-
cal utility of the invention must differ from the practical utility of an existing 
natural product.195 Each court may construe these terms as broadly or as nar-
rowly as it deems appropriate given the circumstances of each case.196 
B. Evaluating Patentable Subject Matter in the Context of Life Sciences 
Methods Using the Transformation-or-Thicket Guidelines 
Just as the modified Chakrabarty standard would elucidate the patent-
able subject matter requirement as applied to life sciences products, the 
transformation-or-thicket standard would clarify which processes in meth-
                                                                                                                           
(2013) (explaining how the U.S. patent system enables American patent-holders to compete with 
international rivals); Gideon Parchomovsky & R. Polk Wagner, Patent Portfolios, 154 U. PENN. 
L. REV. 1, 12 (2005) (arguing that the patent system leads to more efficient production). 
 189 See Johnston, supra note 151, at 85 (explaining that patents can hinder public access to 
medical treatments through the creation of monopolies, and patents on research tools can increase 
the cost of scientific research); Hubbard, supra note 188, at 1910 (stating that policymakers try to 
“balance the incentive effect of U.S. patents against the competitive costs”); Parchomovsky & 
Wagner, supra note 188, at 14 (stating that most U.S. patents are not commercialized and thereby 
“pass their lives in complete idleness, gathering dust rather than revenues”). 
 190 See Myriad, 133 S. Ct. at 2119; Johnston, supra note 151, at 85. 
 191 See Steven J. Hultquist, Reach Through Royalties: The Scope of Research Tool Patents, 86 
J. PAT. & TRADEMARK OFF. SOC’Y 285, 286 (2004) (explaining the consequences of granting 
patents on research tools). 
 192 See Johnston, supra note 151, at 85; Hultquist, supra note 191, at 286. 
 193 See supra notes 170–192 and accompanying text (articulating requirements for patentable 
subject matter under modified Chakrabarty standard). 
 194 See supra notes 170–192 and accompanying text. 
 195 See supra notes 170–192 and accompanying text. 
 196 See supra notes 170–192 and accompanying text. 
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ods in the life sciences context are patentable subject matter.197 A source of 
confusion surrounding process patents is the degree to which the machine-
or-transformation test established by the Federal Circuit in 2008 in In re 
Bilski should be given weight when determining if a process is patentable 
subject matter. 198  Under the transformation-or-thicket standard, courts 
should continue to consider the machine-or-transformation test as an inves-
tigative tool when evaluating whether life sciences research methods that 
involve altering a product of nature constitute patentable subject matter.199 
Courts should additionally consider whether finding that the invention at 
issue is patentable subject matter would lead to the creation of patent thick-
ets.200 If courts do not consider the issue of patent thicket creation, crucial 
research tools could become tied up, which would require scientists to seek 
licensing agreements in order to conduct certain research.201 
A court should not uphold a patent on a method if the party challeng-
ing the patent has proven by clear and convincing evidence that the patent 
(1) could lead to the creation of a patent thicket over a certain category of 
research tools, and (2) such a category of research tools possesses a practi-
cal utility that differs from existing accessible research tools.202 Because 
this standard requires courts to consider both the machine-or-transformation 
test and the aforementioned thicket criteria to evaluate patentable subject 
matter, this Note refers to this standard as the “transformation-or-thicket 
standard.”203 
Similar to the modified Chakrabarty standard, the transformation-or-
thicket standard provides some degree of notice to scientists as to whether 
their methods inventions will be patentable; the standard, however, is still 
somewhat flexible and allows courts to define the terms within the standard 
                                                                                                                           
 197 See infra notes 198–207 and accompanying text. 
 198 See In re Bilski, 545 F.3d 943 (Fed. Cir. 2008) (en banc), aff’d, Bilski v. Kappos, 561 U.S. 
593, 604 (2010). The Federal Circuit explained the machine-or-transformation test by stating that 
a claimed process is patent eligible under § 101 if the process is tied to a machine or apparatus or 
if it transforms something into a different state or thing. 35 U.S.C. § 101; In re Bilski, 545 F.3d at 
954. The U.S. Supreme Court established that the machine-or-transformation test is not the sole 
test for deciding when an invention is a patent eligible process, but it is instead a useful and im-
portant clue, an investigative tool, for determining whether some claimed inventions are processes 
under § 101. 35 U.S.C. § 101; Bilski, 561 U.S. at 604. 
 199 See In re Bilski, 545 F.3d at 954; Moore, supra note 50, at ¶¶ 8–12 (2010) (summarizing 
the Federal Circuit’s explanation of the machine-or-transformation test and explaining the types of 
transformations that would be considered sufficient to satisfy the patentable subject matter re-
quirement). 
 200 See Johnston, supra note 151, at 85 (explaining that patents limit access to materials or 
methods that might lead to the discovery of other important products). 
 201 See Johnston, supra note 151, at 85; Hultquist, supra note 191, at 286. 
 202 See infra notes 204–222 and accompanying text (articulating the requirements for patenta-
ble subject matter under the transformation-or-thicket standard). 
 203 See infra notes 204–222 and accompanying text. 
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as they see fit.204 The goal of the transformation-or-thicket standard is not to 
establish a bright-line test, but to encourage greater scrutiny of inventions 
that could be considered important or basic tools of research.205 Adopting 
such a standard would also encourage parties to rely on experts to testify as 
to why an invention would or would not create a patent thicket.206 The in-
volvement of more individuals with relevant scientific knowledge would 
allow judges and juries, who often have little scientific background, to bet-
ter understand the effect of upholding the patent at issue on the relevant sci-
entific field as a whole.207 
V. APPLYING THE NEW STANDARDS TO PATENTS ON IPS CELL 
TECHNOLOGIES 
Section A of this Part explains how the modified standard of the U.S. 
Supreme Court’s 1980 decision in Diamond v. Chakrabarty would be ap-
plied to patent claims directed to induced pluripotent stem (“iPS”) cell 
lines. 208  Section B explains how the transformation-or-thicket standard 
would be applied to patent claims directed to methods of creating iPS 
cells.209 
A. Under the Modified Chakrabarty Standard, iPS Cell Lines Are Likely to 
Be Considered Patentable Subject Matter 
Under the modified Chakrabarty standard, iPS cells would be found to 
be patentable subject matter.210 Because iPS cells are pluripotent, or can 
differentiate into many types of cells, a court would be likely to find that 
iPS cells possess a “markedly different characteristic” from the skin cells 
                                                                                                                           
 204 See Chakrabarty, 447 U.S. at 310; Johnston, supra note 151, at 85. The patent system 
provides an incentive for scientists to pursue certain areas of research. Johnston, supra note 151, at 
85. In order for this incentive to be in place, scientists must know the boundaries and limitations 
of the patent system. See id. If scientists are unaware of whether their invention is patentable or 
not, such incentive might be diminished. See id. 
 205 See Hultquist, supra note 191, at 286 (explaining the consequences of granting patents on 
critical research tools); Karshtedt, supra note 37, at 949 (proposing that “completeness” be a sepa-
rate requirement of patentability to improve access to research tools). 
 206 See Karshtedt, supra note 37, at 988 n.300 (recognizing that expert testimony can help 
courts to identify broad claims to research tools); Cutting Through the Patent Thicket, BLOOM-
BERG BUS. (Dec. 19, 2005), http://www.bloomberg.com/bw/stories/2005-12-19/cutting-through-
the-patent-thicket [http://perma.cc/2EJX-SRP2] (suggesting that the scientific community should 
be able to comment on patent filings so that the United States Patent and Trademark Office 
(“USPTO”) is informed as to what inventions are truly new). 
 207 See Karshtedt, supra note 37, at 998 n.300; Cutting Through the Patent Thicket, supra note 
206. 
 208 See infra notes 210–222 and accompanying text. 
 209 See infra notes 223–233 and accompanying text. 
 210 See infra notes 211–212 and accompanying text. 
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from which they are derived.211 Furthermore, the court would be likely to 
find that iPS cells possess a combination of practical utilities that no prod-
uct of nature possesses, that combination being: (1) iPS cells are pluripo-
tent, and (2) iPS cells can be obtained without destroying a human em-
bryo.212 
One potential shortcoming of the modified Chakrabarty standard is 
that the term “practical utility” in the context of the second step of the anal-
ysis is left to the courts to interpret and define.213 “Practical utility” should 
be construed narrowly enough such that research tools and other basic ne-
cessities for invention are not tied up by patents.214 At the same time, “prac-
tical utility” should be construed broadly enough such that patents can be 
obtained on biotechnologies without substantial difficulty such that there is 
still incentive to innovate.215 
In the context of iPS cells, a court could find that the ease at which iPS 
cells are obtained as compared to embryonic stem cells (“ESCs”) does not 
warrant a practical utility.216 Such an interpretation, however, would com-
promise the incentive to develop better and more efficient methods of creat-
ing pluripotent stem cells.217 Because the creation of easily obtainable stem 
                                                                                                                           
 211 See Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980) (finding a bacterium with charac-
teristics “markedly different” from any found in nature to be patentable); Narsinh et al., supra note 
173, at 635 (finding significant variation in the differentiation propensities of iPS cells and ESCs); 
Takahashi et al. 2007, supra note 11, at 861. But see Mallon et al., supra note 173, at 376 (finding 
no gene probe with expression that altered significantly between human iPS cells and ESCs). 
 212 See Takahashi et al. 2007, supra note 11, at 861. Adult stem cells are another type of natu-
rally occurring stem cell available to scientists; embryonic stem cells and iPS cells, however, have 
the ability to differentiate into more different types of cells than adult stem cells. See Murnaghan, 
supra note 2. Furthermore, embryonic stem cells and iPS cells can both be maintained in a labora-
tory more easily than adult stem cells. See id. For these reasons, iPS cells would possess a combi-
nation of practical utilities (i.e., a differentiation potential equivalent to that of an embryonic stem 
cell and an ability to be obtained without destroying an embryo) that is not present in any product 
of nature or existing research tool. See id.; Takahashi et al. 2007, supra note 11, at 861. 
 213 See Chakrabarty, 447 U.S. at 310 (finding a bacterium with characteristics “markedly 
different” from any found in nature to be patentable); supra notes 156–196 and accompanying text 
(articulating requirements for patentable subject matter under modified Chakrabarty standard). 
 214 See SHAPIRO, supra note 124, at 120 (describing the problem of patent thickets); Ed Levy 
et al., Patent Pools and Genomics: Navigating a Course to Open Science? 16 B.U. SCI. & TECH L. 
REV. 1, 3 (2010) (explaining that critics of gene patents believe that such patents would disrupt 
scientific research by creating patent thickets). 
 215 See SHAPIRO, supra note 124, at 120 (describing the consequences of granting overly 
broad patents). 
 216 See Chakrabarty, 447 U.S. at 310; supra notes 156–196 and accompanying text (articulat-
ing requirements for patentable subject matter under modified Chakrabarty standard). 
 217 See SHAPIRO, supra note 124, at 121. The availability of patent protection for iPS cells, 
however, would incentivize iPS cell research. See Hubbard, supra note 188, at 1910 (explaining 
that the patent system encourages innovation and allows American inventors to be internationally 
competitive in commercializing their products); Parchomovsky & Wagner, supra note 188, at 12 
(arguing that the U.S. patent system leads to more efficient production). 
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cells is highly economically beneficial, the term “practical utility” should be 
construed to incentivize this activity.218 
Because the modified Chakrabarty standard can be easily applied to 
inventions that are derivatives of natural products, the adoption of the modi-
fied Chakrabarty standard would give iPS cell researchers and other biolo-
gists a better indication of whether their work products are patentable sub-
ject matter.219 This would, in turn, allow them to focus their efforts on tech-
nologies, such as iPS cells, that would be likely to be patent-eligible under 
this standard.220 
Although the modified Chakrabarty standard is fairly easily applied to 
iPS cells, courts might have difficulty applying this standard to inventions 
that are derived from more than one natural product.221 While courts should 
have the discretion to choose what natural product should be used for pur-
poses of the modified Chakrabarty analysis, courts should base their anal-
yses on the one or more natural products that make up the invention in larg-
est part.222 
B. Under the Transformation-or-Thicket Standard, Method Patents Related 
to iPS Cells Would Likely Be Upheld as Valid 
Under the transformation-or-thicket standard, a court would be likely to 
uphold only certain iPS cell preparation methods claims.223 With regard to the 
first element of the test, iPS cells clearly undergo a transition when transfect-
                                                                                                                           
 218 See SHAPIRO, supra note 124, at 121 (describing the patent system as a “spur” to innovation). 
 219 See Chakrabarty, 447 U.S. at 310; supra notes 156–196 and accompanying text (articulat-
ing requirements for patentable subject matter under modified Chakrabarty standard). 
 220 See Takahashi et al. 2007, supra note 11, at 861 (explaining the characteristics and compo-
sition of iPS cells and how they compare to naturally occurring stem cells); supra notes 156–196 
and accompanying text (articulating requirements for patentable subject matter under modified 
Chakrabarty standard). 
 221 See Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. 74, 618 (Dec. 16, 
2014) (to be codified at 37 C.F.R. 1) (recognizing that some nature-based inventions do not have a 
“naturally occurring counterpart”); supra notes 156–196 and accompanying text (articulating 
requirements for patentable subject matter under modified Chakrabarty standard). 
 222 See Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. at 622–23 (ex-
plaining that when a product does not have a “naturally occurring counterpart,” the patent examin-
er should compare the product to the “closest naturally occurring counterpart”); supra notes 156–
196 and accompanying text (articulating requirements for patentable subject matter under modi-
fied Chakrabarty standard). 
 223 See Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 
(2013) (recognizing that, without 35 U.S.C. § 101, patents could be granted on crucial research 
tools, creating patent thickets and thereby hindering scientific research and progress); Ariad 
Pharm., Inc. v. Eli Lilly & Co. (Ariad II), 598 F.3d 1336, 1361 (Fed. Cir. 2010) (explaining how 
the Patent Act balances encouraging innovation and protecting research tools through the require-
ment that patent applicants include a written description of the invention); supra notes 197–207 
and accompanying text (describing the application of the transformation-or-thicket standard to iPS 
cell preparation methods). 
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ed with pluripotency genes.224 A fibroblast, upon transfection, clearly “trans-
forms” into another cell type with different characteristics and capabilities.225 
Therefore, a claim directed to iPS cell preparation methods would clearly 
meet the first element of the transformation-or-thicket analysis.226 
Whether an iPS cell preparation method claim meets the second ele-
ment, however, would depend on the scope of the claim.227 For example, a 
claim teaching a method of iPS cell preparation using a combination of spe-
cific genes, such as Oct3/4, Sox2, c-Myc, and Klf4, would be upheld as pa-
tentable subject matter.228 Since the genes utilized are specifically enumer-
ated, such a claim would be unlikely to create a patent thicket on a broader 
category of research tools.229 A claim teaching a method of iPS cell prepara-
tion using “a combination of pluripotency genes” would be less likely to be 
upheld under the transformation-or-thicket standard, even if the patent 
holder had enabled the creation of iPS cells using many combinations of 
pluripotency genes.230 
Likewise, a claim teaching a method of iPS cell preparation using one 
specifically named gene in combination with other pluripotency genes (e.g., 
using Oct3/4 in combination with one or more pluripotency genes) would 
also be unlikely to be upheld under this standard.231 This is because certain 
                                                                                                                           
 224 See Takahashi et al. 2007, supra note 11 at 862 (comparing the gene expression profile of 
differentiated iPS cells with those of various somatic cell types). 
 225 See Mallon et al., supra note 173, at 376 (observing a high degree of similarity in the gene 
expression patterns and methylation patterns of iPS cells and ESCs); Takahashi et al. 2007, supra 
note 11, at 861 (observing a high degree of similarity between iPS cells and naturally occurring 
stem cells with regard to morphology, surface antigens, and gene expression, among other charac-
teristics). But see Narsinh et al., supra note 173, at 635 (observing variation in the differentiation 
propensities of iPS cells, which could pose an obstacle to researchers seeking to use iPS cells as an 
alternative to ESCs). 
 226 See Mallon et al., supra note 173, at 376 (observing a high degree of similarity between 
iPS cells and ESCs); Takahashi et al. 2007, supra note 11, at 861 (observing a high degree of 
similarity between iPS cells and naturally occurring stem cells with regard to morphology, surface 
antigens, and gene expression, among other characteristics). But see Narsinh et al., supra note 173, 
at 635 (observing variation in the differentiation propensities of iPS cells). 
 227 See Baker, supra note 35 (explaining the techniques by which doctors created iPS cells, 
both using Oct3/4 and Sox2 reprogramming factors); Takahashi et al. 2007, supra note 11, at 861 
(utilizing reprogramming factors Lin28, Nanog, Oct3/4, and Sox2 to create iPS cells). 
 228 See Baker, supra note 35 (describing using Oct3/4, Sox2, Klf4, and c-Myc to create iPS 
cells); supra notes 124–127 and accompanying text (describing the concern surrounding overly 
broad patents in the stem cell field). 
 229 See Hultquist, supra note 191, at 286 (describing how if there were patents on research 
tools, royalties paid on such research tools would be disproportionate to the value realized by the 
user of the research tool). 
 230 See supra notes 197–207 and accompanying text (explaining the requirements for uphold-
ing a patent under the transformation-or-thicket standard). 
 231 See Takahashi et al. 2007, supra note 11, at 862 (utilizing Oct3/4 and Sox2 to create iPS 
cells); supra notes 124–127 and accompanying text (describing the concern surrounding overly 
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genes—namely Oct3/4 and Sox2—are utilized in many known iPS cell 
preparation protocols, which suggests that using one or both of these genes 
could be crucial to iPS cell preparation.232 If the other genes used are not 
specifically enumerated, such a claim could create a patent thicket over all 
methods of cellular reprogramming using Oct3/4 or Sox2, which would 
pose a significant hindrance to scientists in their quests to develop medical 
treatments from iPS cells.233 
VI. WHERE WOULD A VALIDATING OR INVALIDATING DECISION LEAVE 
THE FIELDS OF STEM CELL TECHNOLOGY AND PATENT LAW? 
In addition to articulating a clearer standard by which patentable sub-
ject matter should be evaluated, a court hearing a challenge to an iPS cell 
line or iPS cell preparation patent should pay close attention to the practical 
effects of an invalidating or validating decision on the fields of biological 
research and patent law.234 
Should a patent on any type of iPS cell technology be upheld in an in-
validity challenge, such a result could impact the availability of what are 
now considered to be basic research tools in the life sciences.235 Increasing-
ly, labs across the United States are preparing and manipulating iPS cell 
lines, developing medical treatments and diagnostic methods derived from 
iPS cell lines, and engineering nuclear reprogramming factors.236 Regard-
less of the purpose for which iPS cell labs are using patented iPS cell tech-
nology, it is possible that labs across the country are infringing on existing 
patent rights by using iPS cell lines, preparation methods, or nuclear repro-
                                                                                                                           
broad patents in the stem cell field and the broader policy considerations that the transformation-
or-thicket standard takes into account). 
 232 See, e.g., U.S. Patent No. 7,682,828 (issued Mar. 23, 2010) (claiming an iPS cell prepara-
tion method using Oct3/4 and Sox2); Takahashi et al. 2007, supra note 11, at 861 (utilizing Oct3/4 
and Sox2 to create iPS cells); Yu et al., supra note 72, at 1917 (utilizing Oct3/4 and Sox2 to create 
iPS cells). 
 233 See Hultquist, supra note 191 at 286; e.g., ’828 Patent; Takahashi et al. 2007, supra note 
11, at 861; Yu et al., supra note 72, at 1917. 
 234 See infra notes 236–242 and accompanying text. 
 235 See infra notes 236–242 and accompanying text. 
 236 Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC), 
NAT’L INSTS. OF HEALTH (Feb. 5, 2015), http://report.nih.gov/categorical_spending.aspx [http://
perma.cc/V83S-5KB3] [hereinafter Estimates of Funding]. In 2011, 2012, and 2013, the amount 
given by the National Institutes of Health (“NIH”) in grant money toward non-embryonic stem 
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gramming factors in the labs’ experimentation.237 If a holder of patent rights 
over a certain iPS cell technology were to start suing labs for infringement, 
iPS cell research could come to a temporary halt until the infringing labs are 
able to obtain licensing agreements or develop an alternative method to 
prepare iPS cells without infringing on existing patents.238 
Alternatively, should an iPS cell technology patent be held invalid, 
such a ruling could raise concerns that the court is construing patentability 
requirements too narrowly or ruling in light of hindsight bias.239 Additional-
ly, a finding of invalidity could decrease incentive for scientists to develop 
medical treatments derived from iPS cell technology.240 Until scientists per-
fect a method by which iPS cells can be produced at a relatively high yield, 
scientists will continue to rely in part on embryonic stem cells to conduct 
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https://web.stanford.edu/dept/law/ipsc/pdf/adams-charles.pdf [https://perma.cc/Q6J4-HT3M]. 
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stem cell research.241 Slowing the rate of iPS cell research will only prolong 
scientists’ dependency on embryonic stem cells and, in turn, will prolong 
the embryonic stem cell debate.242 
CONCLUSION 
Given that induced pluripotent stem cell (“iPS cell”) technology is a 
rapidly burgeoning area of biological research that has attracted hundreds of 
scientists across the United States over the past decade, it is likely that 
claims directed toward iPS cell technologies will be challenged in coming 
years. The lack of clarity surrounding the patentable subject matter re-
quirement as it applies to life sciences renders unclear whether iPS cell 
technologies would be invalidated if challenged. In order to encourage re-
search and innovation in the stem cell field, courts should establish clearer 
standards to evaluate patentable subject matter in the context of life scienc-
es products and methods. The modified Chakrabarty standard and the trans-
formation-or-thicket standard would encourage innovation by providing 
clarity in this area. Courts and patent examiners would be given much 
needed guidance with which to determine the patentability of future impact-
ful biological inventions. Accordingly, courts and examiners would be able 
to better balance the patent system’s goal of incentivizing innovation while 
keeping essential research tools in the public domain. 
SARAH SMITH 
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